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ABSTRACT 
 
 
Studies of the Relationship of Protein Structure to Regulation and Catalysis in  
Tyrosine Hydroxylase. (May 2006) 
Giri Raju Sura, B.M.S., University of Health Sciences, India; 
B.S., Osmania University, India; 
M.S., Punjabi University, India 
Chair of Advisory Committee: Dr. Paul F. Fitzpatrick 
 
Tyrosine hydroxylase (TyrH) catalyzes the rate-limiting step in the synthesis of 
the catecholamine neurotransmitters dopamine, epinephrine, and norepinephrine. 
Phosphorylation of Ser40 of rat TyrH activates the enzyme by decreasing the affinity for 
catecholamines. In humans, there are four different TyrH isoforms with varying lengths 
for the regulatory domain. DOPA and dopamine binding studies were performed on the 
phosphorylated and unphosphorylated human isoforms. The Kd for DOPA was increased 
two times upon phosphorylation of hTyrH1, but no change was seen for hTyrH4; the Kd 
value decreased with the increase in the size of regulatory domain. The small effect on 
the Kd value for DOPA upon phosphorylation of hTyrH suggests that DOPA does not 
regulate the activity of hTyrH. Dopamine binds very tightly and upon phosphorylation 
the affinity for dopamine is decreased. This Kd value decreases with the increase in the 
length of the regulatory domain.  
The crystal structures of substrate complexes of the homologous enzyme 
phenylalanine hydroxylase (PheH) show a large movement of a surface loop (residues 
131-155) upon amino acid binding. The corresponding loop residues (175-200) in TyrH 
play an important role in DOPA formation. This conformational change in TyrH loop 
was studied with fluorescence anisotropy. Three tryptophan residues in the TyrH, at 
positions 166, 233, and 372, were mutated to phenylalanine, and Phe184 was mutated to 
tryptophan. An increase in anisotropy was observed in the presence of phenylalanine and 
6-methyl-5-deazatetrahydropterin (6M5DPH4), but the magnitude of the change of 
  
iv 
anisotropy with 6M5DPH4 was greater than that with phenylalanine. Further 
characterization of the sole tryptophan in the loop showed a decrease in the amplitude of 
the local motion only in the presence of 6M5DPH4 alone.  
The conformational change in wild type TyrH was examined by H/D exchange 
LC/MS spectroscopy in the presence of the natural ligands. Time-course dependent 
deuterium incorporation into the loop in the presence of ligands indicated that the pterin 
alone can induce the conformational change in the loop irrespective of whether iron is 
reduced or oxidized. From these results, one can conclude that the loop undergoes a 
conformational change upon pterin binding, making the active site better for amino acid 
binding.  
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CHAPTER I 
INTRODUCTION 
 
Enzymes are important biocatalysts. While the biocatalytic function lies in active 
site residues, the whole structure is important. The residues that are not participating in 
catalysis will help in aligning the active site residues and may perform additional 
functions such as regulation. Enzymes have evolved to use cofactors and/or redox active 
metal centers capable of donating a single electron to activate dioxygen. The enzymes 
tyrosine hydroxylase (TyrH, EC 1.14.16.2), phenylalanine hydroxylase (PheH, EC 
1.14.16.1) and tryptophan hydroxylase (TrpH, EC 1.14.16.4) are pterin-dependent 
monooxygenases which catalyze the aromatic hydroxylation of their respective 
substrates (Scheme 1). The iron-dependent aromatic amino acid hydroxylases perform 
monooxygenase reactions utilizing tetrahydrobiopterin (BH4) as the source of electrons. 
One atom of oxygen is incorporated into the amino acid and the other atom goes to the 
pterin and subsequently to form water (1). The eukaryotic forms of these enzymes have 
been studied because of their physiological importance. PheH is a liver enzyme (2), 
essential for the catabolism of phenylalanine to tyrosine. A deficiency of this enzyme 
causes phenylketonuria. TyrH is found in the central nervous system and the adrenal 
gland (3). The enzyme catalyzes the rate limiting step in the formation of the 
catecholamine neurotransmitters dopamine, epinephrine, and norepinephrine, the 
formation of dihydroxyphenylalanine (DOPA) from tyrosine. A deficiency of TyrH 
causes DOPA-responsive dystonia and Parkinson’s disease (4-6). TrpH is also found in 
the brain where it catalyzes the first step in serotonin biosynthesis, the hydroxylation of 
tryptophan to 5-hydroxytryptophan. Decreased levels of serotonin have been implicated 
in depression, alcoholism, and impulsive violence (7-9). 
 
____________ 
This dissertation follows the style of Biochemistry. 
  
2 
Scheme 1 
HO
CO2-
NH3+
PheH
N
H
H
N
NH
N
H
H
H
C
H O
NH2
O2
N
H
H
N
N
NHH
R
H O
NH2
O
H
CO2-
NH3+
H
C
OHOH
H3C
HO
CO2-
NH3+
HOTyrH
N
H
NH3+
CO2-
N
H
NH3+
CO2-
HOTrpH
HO
CO2-
NH3+
 
 
 
The eukaryotic amino acid hydroxylases are homotetramers (10-12). An 
equilibrium between a homodimer and a homotetramer exists only in PheH, whereas 
TyrH and TrpH are reported to be exclusively homotetramers (12). Each enzyme 
consists of three distinct domains: varying lengths of an N-terminal regulatory domain 
with little similarity among the three enzymes, a homologous C-terminal catalytic 
domain and a tetramerization domain. All three eukaryotic enzymes are regulated by 
phosphorylation of serine residues in the regulatory domain. In the case of PheH, 
phosphorylation activates tyrosine formation about threefold, possibly by altering the 
equilibrium between open and closed forms of the enzyme (13). In the case of TyrH, 
phosphorylation removes the effect of inhibition by catecholamines (14, 15). The role of 
phosphorylation has not been determined in TrpH. The crystal structures of the catalytic 
domains of the eukaryotic enzymes as well as of the intact PheH from C. violaceum have 
been determined (16). The catalytic domain structures for TyrH, PheH and TrpH with 
iron and pterin bound have been determined (17-21). A crystal structure with only amino 
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acid substrate bound has not yet determined. However, a structure is available for the 
human PheH catalytic domain with tetrahydrobiopterin and -thienylalanine bound (22). 
 
 
A B
FIGURE 1. (A) Overlay of the -C trace of the catalytic domain of human PheH (1J8U-
red), rat TyrH (2TOH-green), and human TrpH (1MLW-black). The iron atom (blue) is 
shown to denote the active site. (B) 2-His-1-carboxylate facial triad with iron (black) of 
human TyrH (2TOH). 
 
 
The catalytic domains of the three eukaryotic enzymes have similar structures 
(Figure 1A). Although the three enzymes share a homologous catalytic domain, each has 
a preference for its corresponding amino acid (23-25). PheH can hydroxylate 
phenylalanine and tryptophan, though tryptophan is a poorer substrate (13). TyrH can 
hydroxylate all three substrates with the preference of 
tyrosine>phenylalanine>tryptophan (26, 27). TrpH can also hydroxylate all three 
substrates with preferences for tryptophanphenylalanine>>tyrosine (28).  
The overall structure of the catalytic domain is cup-like, with a deep active center 
which contains one iron atom per subunit. The iron lies at the bottom of a 10 Å deep 
cleft where it is bound to two histidines and one glutamate in a facial triad. In TyrH 
these residues are His331, His336 and Glu376 (Figure 1B); the corresponding residues 
in PheH are His285, His290 and Glu330. The 2-his-1-carboxylate motif is common in 
mononuclear, non-heme iron dependent mono and dioxygenases (29). In the Fe(III) 
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forms of the aromatic amino acid hydroxylases, the two histidine residues and the 
glutamate residue are joined by 3 water molecules in a distorted octahedral coordination 
(Figure 1B) (17-19). Structures of human PheH with ferrous iron have been determined 
both with tetrahydrobiopterin alone and with tetrahydrobiopterin and -thienylalanine 
(20, 22). By comparing these structures, the changes in the active site upon amino acid 
binding to PheH can be described (Figure 2). When only BH4 is bound, the iron is bound 
by His285, by His290, by Glu330 through monodentate coordination and by three waters 
(Figure 2A). In the PheH•BH4•-thienylalanine complex, glutamate 330 shifts to a 
bidentate coordination of the iron atom, and two of the water molecules dissociate. The 
iron is then five coordinate, square pyramidal, providing one open coordinate site for 
molecular oxygen. Differences between the binary and ternary complexes are not limited 
to the active site region. A loop consisting of residues 131-150 closes over the active site 
in the ternary complex. This movement shifts the side chain of Tyr138 about 20 Å into 
the active site to complete the binding site for the amino acid side chain.  
According to induced-fit model (30), conformational changes in enzymes are 
necessary for substrate binding and catalysis. These conformational changes vary from 
domain movements to local loop movements (31, 32). These protein movements 
facilitate the binding of substrates, catalysis and release of products. For example, in 
human hypoxanthine guainine phosphoribosyltransferase, the crystal structure with the 
transition state analog immucillinGP and Mg2+-pyrophosphate bound shows that the 
transition state is shielded from solvent by antiparallel β-strands. In the absence of 
ligands, these strands form a single random loop. This loop is proposed to recognize the 
substrate and shield the transition state from bulk water (33). Crystal structure of 
complexes of enzyme with substrates and transition state analogs can identify changes in 
structure but provide no information on the rates of which structural changes occur. A 
given structural change can be much faster than catalysis or rate-limiting for turnover. 
These structural changes span a wide range of time scales. The conformational changes 
that occurs on a µs to ms time scale can be identified by NMR spectroscopy  (34) and  
those occurring over pico seconds to ns can be identified by fluorescence spectroscopy 
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(35), (36). NMR spectroscopic studies are applicable to small proteins and can give 
information for individual residues. In the case of triosephosphate isomerase, the solid 
state deuterium NMR spectrum of the protein with a single deuterium-labeled tryptophan 
in the loop6 hinge region reveals that the loop moves at a rate of 104 sec-1 and this 
matches to the turnover number (37). Further, studies with 5-fluorotryptophan in the 
loop and 31P-labelled substrate analogues using solution-state NMR spectroscopy 
revealed that product release is partially rate determining. T-jump relaxation 
spectroscopy revealed that the loop is closed only during catalysis (37-39). Thus in TIM 
a variety of approaches establish the importance of protein motions in catalysis. As a 
further example human cyclophillin A, a peptidy-prolyl  cis/trans isomerase, catalyzes 
isomerization of its  substrate at 9000 s-1, and protein motions around the active site 
observed by NMR relaxation methods coincide with the rate of substrate rotation (40). 
Nanosecond movements around the active site in acetylcholinesterase could be observed 
by time-resolved fluorescence anisotropy (36). In recent years, several studies have been 
reported in which mass spectroscopy was used to use the H/D exchange behavior of 
water soluble proteins to probe their secondary structural changes under a wide variety 
of environmental conditions such as pH, temperature and ionic strength. H/D exchange 
rates are the rates for the amides in an entire peptide rather than for individual amides. 
Crystal structures of glutathione transferase suggest that the barrier for product release is 
a hydrogen bond between Tyr115 and Ser209. The crystal structures of the Y155F 
mutant did not show significant changes, but the mutant protein exhibited a 3 fold 
increase in activity. However, the H/D exchange mass spectroscopy of this mutant 
showed a 3-fold increase in exchange kinetics for the peptide at the access channel, 
suggesting that segmental motion in glutathione transferase is indeed responsible for the 
product release (41).   
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A 
 
 
B 
FIGURE 2. Comparison of the active site architecture of PheH-Fe(II) in the presence 
and absence of bound amino acid. (A) With BH4 alone (PDB-1J8U) (B) With both BH4 
and thienylalanine (PDB-1KW0). 
 
 
All members of the aromatic amino acid hydroxylase family require one atom of 
ferrous iron per subunit for activity (42, 43). Studies with rat TyrH have shown that 
other divalent metals will not support amino acid hydroxylation (44). Mutations of 
His285 or His290 in PheH to serine, and of His331 or His336 in TyrH to alanine abolish 
the activity (45, 46). TyrH His331E shows a decrease in affinity for iron but oxidizes 
tetrahydropterin in the absence of amino acid. TyrH His336Q retains hydroxylase 
activity but oxidation of pterin is poorly coupled to hydroxylation of amino acid (47). 
The iron atom is still required for tetrahydropterin oxidation. H336Q TyrH can utilize 
Co(II) to catalyze the oxidation of tetrahydropterin but not amino acid hydroxylation 
(48). The Co(II) atom would be able to form a peroxy species to promote 
tetrahydropterin oxidation; however, it has difficulty attaining a Co(IV) oxidation state. 
These results suggest that iron is strictly required to form the hydroxylating intermediate, 
but that other metals can support the oxidation of tetrahydropterin. In accordance with 
this proposal, computational studies of PheH have shown that the oxygen first interacts 
with the iron to form a Fe(III)-O2- species which can then go on to form the 
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hydroxylating intermediate (49). However, this study was based on the structure of the 
catalytic domain of PheH with only tetrahydropterin bound. As stated above, substantial 
active site rearrangement occurs upon amino acid binding which may have an effect on 
the computational studies.  
Pterin binds in a hydrophobic pocket in the active site through a stacking 
interaction with Phe254 in PheH or Phe300 in TyrH and numerous backbone and water-
mediated hydrogen bonds (50). Glu332 of TyrH helps in keeping proper orientation of 
the pterin during catalysis (51) and interact with 7,8-dihydrobiopterin through a water 
molecule, whereas the corresponding residue Glu286 in PheH forms direct hydrogen 
bonds with BH4. The C-4a atom of the tetrahydrobiopterin is within 4.5 Å of the open 
face of the iron atom, a distance which can accommodate a dioxygen molecule. In the 
PheH complex with -thienylalanine and tetrahydropterin the amino acid side chain is in 
a hydrophobic pocket formed by Trp326, Phe331 and Pro 281 and the peptide back bone 
of Gly346. The amino group of Arg270 and the carboxylate group of Asp282 form 
electrostatic interactions with the carboxylate of the amino acid. The corresponding 
residue in TyrH is Arg316. Mutation of Asp328 to alanine and Arg316 to lysine greatly 
decreases the affinity of TyrH for tyrosine (51).  
Until 1991, little was known about the catalytic mechanism of TyrH. Fitzpatrick 
showed that substrate binding is ordered with the pterin binding first, oxygen second, 
and finally tyrosine (52). A proposed chemical mechanism is shown in Scheme 2 (53). 
The mechanism can be broken down into two major steps, oxygen activation and amino 
acid hydroxylation. After all substrates are bound, the first step is a single electron 
transfer from the tetrahydropterin to oxygen to form a superoxide anion and a pterin 
cationic radical. This step is analogous to oxygen activation by the flavin hydroxylases 
and resembles the initial steps in tetrahydropterin auto-oxidation (54). Large 18O isotope 
effects support a change in the bond order to oxygen in the first irreversible step (55). 
The same effect is found when a substrate which uncouples oxygen activation from 
amino acid hydroxylation is used, suggesting that oxygen activation does not involve the 
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amino acid substrate. Kinetic studies with alternate substrates for TyrH establish oxygen 
activation as rate-limiting (27, 56, 57). 
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Following formation of the tetrahydropterin cation radical, the radical pair 
recombines to form an oxygen bridged iron-pterin species. This species undergoes 
heterolysis to form a high-valence, ferryl-oxo [Fe(IV)=O] species and 4a-hydroxypterin. 
Mutagenesis of charged active site residues has not revealed a protein based source of 
the required proton, suggesting that the proton is solvent derived (51). A deuterium 
solvent isotope effect of 1 is seen for wild-type TyrH, consistent with oxygen activation 
being the rate limiting step (27). In PheH, the peroxy-pterin species was proposed to be 
the hydroxylating intermediate in analogy to the flavin-monooxygenase family (58). In 
this case, production of the 4a-hydroxypterin and hydroxylation of the amino acid must 
be concerted. When serine 395 in TyrH, which is in the secondary coordination sphere 
of the iron, is changed to alanine, the enzyme forms 4a-hydroxypterin at a rate 
comparable to the wild-type enzyme but only forms DOPA at a rate 1-2% that of the 
wild type enzyme (59). This result suggests that cleavage of the O-O bond creates the 
hydroxylating intermediate, the proposed ferryl-oxo species. While there is no direct 
spectroscopic evidence for a ferryl-oxo species in the reaction catalyzed by TyrH, a 
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similar species has recently been characterized as an intermediate in taurine/-
ketoglutarate dioxygenase, another member of the 2-his-1-carboxylate family (60). The 
ability of the pterin-dependent monooxygenases to catalyze benzylic hydroxylation also 
supports the involvement of a very strong oxidant. PheH and TyrH will hydroxylate 4-
methyl-phenylalanine to form 4-hydroxymethyl-phenylalanine (56, 61). TrpH will 
hydroxylate 5-methyl-tryptophan to form 5-hydroxymethyl-tryptophan (62). Finally, 
computational studies are consistent with the involvement of a Fe(IV)=O intermediate in 
aromatic and benzylic hydroxylation by the aromatic amino acid hydroxylases (49). 
Once formed, the proposed ferryl-oxo intermediate reacts with the aromatic ring through 
an electrophilic aromatic substitution mechanism, creating a cationic intermediate. 
Evidence for this intermediate comes from analyses of product formation using 4-X-
phenylalanine substrates. The amount of product formed was proportional to the 	 value 
for the substitute, giving a 
 value of –5 and suggesting an electron deficient transition 
state (56). This mechanism predicts an inverse secondary isotope effect on the rate of 
hydroxylation when ring-deuterated tyrosine is used as a substrate. In fact, when 5-2H-
tryptophan is used as a substrate for TrpH, an inverse isotope effect of 0.93 is seen (57). 
However, when 3,5-2H2-tyrosine is used as a substrate for TyrH, no significant isotope 
effect is seen (27, 27). This result is consistent with oxygen activation being the rate-
limiting step. Following cleavage of the iron-oxygen bond, there is loss of a proton and 
rearomatization to form L-DOPA. The 4a-hydroxypterin dehydrates to form quinonoid 
dihydropterin, which tautomerizes in solution to 7,8-dihydropterin (Scheme 3) (63). In 
vivo, the quinonoid dihydropterin is reduced by dihydropterin reductase (64).  
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As the catalyst for the rate-limiting step in neurotransmitter production, TyrH is 
tightly regulated. The activity is regulated at both the transcriptional and 
posttranslational level (65, 66). Short-term regulation of catecholamine biosynthesis 
involves the reversible phosphorylation of serine residues in the regulatory domain of 
TyrH. Rat TyrH is phosphorylated at four serine residues in its amino-terminal 
regulatory domain by different kinases. The multisite phosphorylation of TyrH is not 
unique. Many proteins involved in second messenger cascades are phosphorylated by 
multiple kinases. Multiple phosphorylation can be required for translocation in the cell, 
for ubiquitination, to signal a phosphatase or an effector such as 14-3-3 protein (67). In 
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TyrH, a cdc2/cyclin kinase and extra cellular signal-regulated kinase 2 (ERK 2) ERK2  
(68) phosphorylate Ser8 (69, 70). Ser19 is phosphorylated by p38 regulated/activated 
kinase (71). Both Ser19 and Ser40 are phosphorylated by calmodulin-dependent protein 
kinase with more preference for Ser19 (72) and by mitogen-activated protein kinase 2 
(MAPKAP 2) with more preference for Ser40 (73). The target of cyclic dependent 
kinase 5 (Cdk5) and ERK2  (68) is Ser31.  Cyclic AMP-dependent protein kinase (PKA) 
(72), protein kinase C (74), mitogen-activated  protein kinase-activated protein kinase1 
(MAPKAP kinase 1) (73), mitogen and stress-activated protein kinase 1 (71), and 
cGMP-Dependent protein kinase (75) all catalyze the phosphorylation of Ser40 (Figure 
3). 
 
FIGURE 3. Schematic diagram of TyrH with phosphorylation sites along with protein 
kinases. 
 
TyrH is regulated by feedback inhibition due to its product DOPA binding to the 
ferric iron (Scheme 4). In TyrH, Daubner et al. reported that activation of tyrosine 
hydroxylase by phosphorylation of Ser40 is due to alleviation of inhibition by 
catecholamines (15, 76). Phosphorylation of Ser40 in TyrH results in a 17-fold decrease 
in affinity for DOPA and in a 300-fold decrease in the affinity for dopamine. A 
structural change between residues 33-50 in the regulatory domain upon phosphorylation 
at Ser40 makes the region trypsin sensitive whereas dopamine bindig does not (77). The 
phosphorylation of serines by different kinases under different conditions with different 
specificities has complicated the understanding of the TyrH activity.  Mutational studies 
    Ser8    Ser19       Ser31   Ser40 
cdc2/cyclin2      CaM PKII        ERK 1&2          PKA 
ERK 2               MAPKAP 2     Cdk5                CaM PKII 
                                                                          MAPKAP 1&2  
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of serines to glutamate to mimic isosteric serine-phosphorylation and to alanine to mimic 
unphosphorylation have been carried out. A negative charge at Ser8, Ser19 and Ser31 
does not significantly affect the binding of DOPA and dopamine, but does increase the 
thermal stability (78). To restore catalytic activity the ferric iron must subsequently be 
reduced. Tetrahydropterins are capable of reducing the iron, and they are proposed to be 
the reductant in vivo due to their role as substrate for the enzyme (79, 80). 
The situation in human TyrH is somewhat complicated because of four different 
isoforms. These isoforms are formed due to differential splicing of mRNA. hTyrH 
isoform 1 corresponds to rat enzyme, hTyrH2 contains four amino acid residues after 
Met30, hTyrH3 contains 27 residues inserted after Met30, and hTyrH4 contains 31 
amino acid residues consisting of the insert in hTyrH2 followed by that in hTyrH3. 
 The combined data from mutational and spectroscopic studies have resulted in 
an understanding of the mechanism of regulation in human isoforms and protein 
dynamics upon ligand binding. This dissertation will describe experiments and results 
which report on the regulatory role of the human isoforms and on the loop movement in 
the catalytic domain upon ligand binding. 
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CHAPTER II 
THE EFFECTS OF PHOSPHORYLATION OF SER40 OF THE HUMAN 
TYROSINE HYDROXYLASE ISOFORMS ON CATECHOLAMINE BINDING* 
 
INTRODUCTION 
The biosynthesis of the catecholamine neurotransmitters begins with the 
hydroxylation of tyrosine to form dihydroxyphenylalanine (DOPA) (Figure 4). This step, 
catalyzed by the enzyme tyrosine hydroxylase (TyrH), is generally accepted to be the 
rate-limiting step in the pathway (81). The TyrH reaction is a monooxygenation, in that 
molecular oxygen is the source of the atom of oxygen incorporated into DOPA (82), 
while tetrahydrobiopterin serves as the source of the two electrons required for reduction 
of the other atom of oxygen to the level of water. Activation of oxygen for the reaction 
involves an active site nonheme iron atom; for catalysis, the iron atom must be in the 
ferrous form (44). In the presence of oxygen the iron is readily oxidized to the ferric 
form; tetrahydropterins can reduce the iron back to the active ferrous state (79). The 
active site containing this iron atom is a deep cleft in a catalytic domain of about 300 
amino acids that is homologous to the catalytic domains of the two other pterin-
dependent aromatic amino acid hydroxylases, phenylalanine hydroxylase and tryptophan 
hydroxylase (17, 83).  
 
 
 
 
_____________ 
*Reproduced with permission from “Effects of Phosphorylation by Protein Kinase A on 
Binding of Catecholamines to the Human Tyrosine Hydroxylase Isoforms” by Sura, 
G.R., Daubner, S.C. and Fitzpatrick, P.F, 2004, J. Neurochem. 90, 970-980, Copyright 
2004 by Blackwell (84). 
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FIGURE 4. Catecholamine biosynthesis: Aromatic amino acid decarboxylase 
(AAADC), dopamine--hydroxylase (DBH) and phenylethanolamine-N-methyl 
transferase (PNMT). 
 
In humans, tissue-specific expression of four different TyrH isozymes has been 
reported (85). This protein diversity is generated through alternative splicing of the pre-
mRNA from the single TyrH gene (85). The differences among the isozymes are all 
limited to the regulatory domain (Figure 5). Isoform 1 most closely resembles rat TyrH. 
Isoform 2 contains an additional 4 amino acids between amino acids 30 and 31 of 
isoform 1, isoform 3 contains an insertion of 27 amino acids at the same point and 
isoform 4 contains both insertions, giving 31 additional residues at the same position. All 
four isoforms have been found in human brain (86). Isoforms 1, 2 and 4 have been 
reported in human adrenal medulla, whereas isoform 1 and 2 are predominant in the 
locus coeruleus and substantia nigra of brain (85). Each human TyrH isoform has a 
serine homologous to Ser40 of rat TyrH, the serine modified by cAMP-dependent 
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protein kinase A (PKA). In the human isozymes these serines are numbered 40, 44, 67 
and 71 (Figure 5).  
 
rTyrH  MATPSAPSPQPKGFRRAVSEQDAKQAEAVT-------------------------------SPRFIGRRQS 40 
hTyrH1 MATPDATTPQAKGFRRAVSELDAKQAEAIM-------------------------------SPRFIGRRQS 40 
hTyrH2 MATPDATTPQAKGFRRAVSELDAKQAEAIMVRGQ---------------------------SPRFIGRRQS 44 
hTyrH3 MATPDATTPQAKGFRRAVSELDAKQAEAIM----GAPGPSLTGSPWPGTAAPAASYTPTPRSPRFIGRRQS 67 
hTyrH4 MATPDATTPQAKGFRRAVSELDAKQAEAIMVRGQGAPGPSLTGSPWPGTAAPAASYTPTPRSPRFIGRRQS 71 
FIGURE 5. N-Terminal amino acid sequences of human TyrH and rat TyrH. The 
remaining sequence is identical among the human TyrH isoforms. The phosphorylated 
serine residues in rat are shown in bold. 
 
All three enzymes also contain N-terminal regulatory domains. The sequences of 
these regulatory domains differ among the three enzymes, consistent with their discrete 
regulatory properties. In the case of TyrH, short term increases in the formation of 
DOPA in vivo correlate with increased phosphorylation of serine residues in this 
regulatory domain (65, 87). In rat TyrH, the serine residues which exhibit altered 
phosphorylation when dopamine biosynthesis is stimulated are located at positions 19, 
31, and 40; Ser8 has also been found to be phosphorylated in adrenal cells, but no 
physiologically relevant conditions which alter its level of phosphorylation have been 
described (87). A large number of studies have examined the effects of such 
phosphorylation on the catalytic activity of TyrH in vitro, utilizing protein kinases 
specific for selected sites (65, 66, 81). cAMP-Dependent protein kinase A (PKA) was 
demonstrated early on to be specific for Ser40 (72), and more recently the MAP kinases 
ERK1 and ERK2 have been demonstrated to phosphorylate Ser31 (88, 89). No kinase 
specific for Ser19 has been described to date, but several will phosphorylate both Ser19 
and Ser40 (72, 73). Activation of TyrH upon phosphorylation by PKA has been 
demonstrated by a number of laboratories (65, 66, 81). However, the effects on the 
enzyme activity are quite modest, changes of about two-fold in the Km value for 
tetrahydrobiopterin (76, 90) and the Ki value for dopamine (90), when purified 
recombinant enzyme is used. The degree of activation upon phosphorylation by a MAP 
kinase is smaller (73, 88), while phosphorylation of both Ser19 and Ser40 has a 
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comparable effect to phosphorylation of Ser40 alone (73). In the case of rat TyrH, Ser40 
phosphorylation results in much more dramatic effects on the affinity of the ferric 
enzyme for catecholamines due to modest increases in the rate constants for binding of 
catecholamines and much larger increases in the rate constants for dissociation (15, 91). 
The greatest effects are seen upon binding of dopamine, norepinephrine, and 
epinephrine; the rate constants for dissociation of all three increase by three orders of 
magnitude when Ser40 is phosphorylated, while the dissociation rate constants for 
DOPA increase about 20-fold. These results are consistent with the model of Scheme 4 
for the effects of Ser40 phosphorylation on rat TyrH (15, 76). The active ferrous form of 
the enzyme catalyzes the formation of DOPA from tyrosine. This form of the enzyme 
can be oxidized to the inactive ferric form; reduction by tetrahydrobiopterin restores 
activity. However, if a catecholamine accumulates in the cell, it can bind to the ferric 
enzyme, trapping it in the inactive complex. Consistent with such a model, when TyrH is 
isolated from rat or bovine cells, it is in the form of a complex containing ferric iron and 
bound catecholamines (92, 93). The rate constants for dissociation of dopamine, 
norepinephrine, and epinephrine from the rat enzyme suggest that catecholamine binding 
to the ferric enzyme is effectively irreversible in the cell until Ser40 is phosphorylated 
(91). 
In humans four different TyrH isoforms are synthesized from this single gene by 
differential splicing (85, 94, 95). Characterization of recombinant forms of all four 
human isoforms has shown that their steady state kinetic parameters are not dramatically 
different (43, 90, 96), although hTyrH1 is reported to have a slightly higher Km for 
tetrahydrobiopterin (90). The effects of phosphorylation by different kinases on steady 
state kinetic parameters are reported to be comparable for all four isoforms (73), 
although there is one report that hTyrH3 is not activated significantly upon 
phosphorylation by PKA (97). However, as noted above the primary effect of 
phosphorylation on the rat enzyme is not on the steady state kinetic parameters but on 
the binding of inhibitory catecholamines. The goals of the experiments described here 
were to determine if the mechanism of Scheme 4 was equally applicable to human and 
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rat TyrH and whether the different human isoforms differ in the effect of 
phosphorylation of Ser40 on the binding of DOPA and dopamine. 
 
EXPERIMENTAL PROCEDURES 
Materials. L-Tyrosine was purchased from Sigma Chemical Corp., St Louis, 
MO. 6-Methyltetrahydropterin (6MPH4) was purchased from B. Schircks Laboratories. 
All other reagents were of the highest purity commercially available. The catalytic 
subunit of beef heart PKA was purifed by the method of Flockhart and Corbin (98). 
Construction of vectors for expression of human tyrosine hydroxylase isoforms in 
E. coli. Plasmid pHTh-63, which contains the cDNA for hTyrH2, was a gift from Dr. 
Karen O’ Malley, Washington University, St. Louis. PCR was used to add an NcoI site 
at the 5’ end of the coding region and a BamHI site at the 3’ end, allowing insertion into 
the pET-23d expression vector (Novagen). Plasmids containing hTyrH2 cDNA were 
identified by restriction enzyme digestion and confirmed by sequencing; the plasmid 
selected for further use was named p23dHTH2. To obtain the other human isoforms, 
modifications of the QuikChange method (Stratagene) were used to delete or insert DNA 
coding for multiple amino acids. To obtain p23dHTH4, the plasmid for expression of 
hTyrH4, two separate PCR reactions, each containing only one of the oligonucleotides in 
Table 1, were run for five cycles. The two reactions were then combined for twelve 
additional PCR cycles. To obtain the plasmids for expression of hTyrH1 and hTyrH3, 
p23dHTH1 and p23dHTH3, respectively, the oligonucleotides in Table 1 were used to 
delete 12 base pairs after the codon for Met30, using p23dHTH2 and p23dHTH4 as 
templates. To avoid formation of dimers between the primers, only one oligonucleotide 
primer was present for the first PCR cycle, and the other was then added for the 
remaining 17 cycles. The desired plasmids were identified by restriction digestion and 
confirmed by sequencing. 
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Table 1. Oligonucleotides Used for Construction of Expression Plasmids for Human 
Tyrosine Hydroxylase Isoforms. 
Modification Product Plus strand 
oligonucleotide 
Minus strand 
oligonucleotide 
Deletion of 12 base 
pairs from p23dHTH2 
p23dHTH1 5’-GGCAGAGGCCAT 
CATGTCCCCGCGGT
TATTGGG-3’ 
5’-CCCAATGAACCG 
CGGGGACATGATGG
CCTCTGC-3’ 
Insertion of 81 base 
pairs into p23dHTH2 
p23dHTH4 5'-CCGTGGCCTGGAA 
CTGCAGCCCCAGCT
GCATCCTACACCCC
CACCCCAAGGTCCC
CGCGGTTCATTGGG
CG-3' 
5'-GCAGTTCCAGGC 
CACGGAGAGCCTGT
GAGGCTGGGCCCCG
GGGCGCCCTGCCCTT
TACCATGATGGCTCT
GC-3’ 
Deletion of 12 base 
pairs from p23dHTH4 
p23dHTH3 5’-GCAGGCAGAGGC 
CATCATGGGCGCCC
CGGGGCCCAGCCTC
ACAG -3’ 
5’-GCTGGGCCCCG 
GGGCGCCCATGATG
GCCTCTGCCTGCTTG
GC -3’ 
 
 
Purification. Expression and purification of the human enzymes was performed 
using modifications of methods developed for the rat enzyme (76). E. coli BL21 StarTM 
(DE3) cells transformed with p23dHTH1, p23dHTH2, p23dHTH3 or p23dHTH4 were 
grown in Luria Bertani medium containing 100 µg/ml carbenicillin at 25˚C. When the 
absorbance at 600 nm reached 0.5, expression was induced with 0.5 mM isopropyl-ß-D-
thiogalactopyranoside. After 6 hours, cells were harvested by centrifugation and 
resuspended in 75 µM diethylenetriaminepentaacetic acid (DTPA), 10% glycerol, 1 µM 
pepstatin, 1 µM leupeptin, 100 µg/ml phenylmethylsulfonylflouride, 25 µg/ml lysozyme, 
50 mM HEPES, pH 7.0. The cells were lysed by sonication at 4 ˚C and centrifuged at 
28,000 x g for 30 min. Streptomycin sulfate was added to the supernatant to a final 
concentration of 1% to allow precipitation of nucleic acids at 28,000 x g for 20 min. The 
resulting supernatant was made 45% saturated in ammonium sulfate, stirred for 20 min 
and centrifuged for another 20 min. The resulting pellet was resuspended in 75 µM 
DTPA, 10% glycerol, 50 mM HEPES, pH 7.0, and dialyzed against the same buffer. 
After centrifugation to remove precipitated protein, the sample was loaded onto a Hitrap-
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Heparin column; this was eluted with a linear gradient of 0-0.8 M KCl in 75 µM DTPA, 
10% glycerol, 50 mM HEPES, pH 7.0. Fractions containing tyrosine hydroxylase were 
pooled and precipitated by making the solution 65% saturated in ammonium sulfate. The 
pellet was resuspended to give a concentration of ~300 µM TyrH in 100 mM KCl, 10% 
glycerol, 1 µM pepstatin, 1 µM leupeptin, 50 mM HEPES, pH 7.0. To this, ferrous 
ammonium sulfate was added to give a 20% molar excess of iron over TyrH active sites; 
excess iron was removed by dialysis (91). All protein purification steps were carried out 
at 4 ºC. Purified enzymes were stored at -80 ˚C. Typical yields were 150-200 mg of pure 
protein from 6 L of culture. 
Assays. The iron contents of the purified enzymes were determined by atomic 
absorption spectrophotometry as previously described for the rat enzyme (79). 
Concentrations of the purified proteins were determined using an A280
1%
 
 value of 10.4 
(92). A colorimetric end point assay for DOPA was used to measure tyrosine 
hydroxylase activity (52). Assays were carried out in 100 µg/ml catalase, 1 mM 
dithiothreitol, 10 µM ferrous ammonium sulfate, at 32 ºC. Standard conditions include 
0.5 µM enzyme, 400 µM 6MPH4 and 200 µM tyrosine in 50 mM HEPES, pH 7.0. For 
determination of the Km value for tyrosine, assays contained 400 µM 6MPH4 and 10 to 
360 µM tyrosine. For determination of the Km value for 6MPH4, assays contained 200 
µM tyrosine and 10 to 360 µM 6MPH4. 6-Methyltetrahydropterin was used as substrate 
because the substrate inhibition seen with tyrosine in this case is much less than when 
tetrahydrobiopterin is used, allowing intrinsic kinetic parameters to be more readily 
measured (52). To obtain the kinetic parameters in Table 2, the kinetic data were fit to 
the Michaelis-Menten equation using the program KaleidaGraph (Synergy Software). 
Phosphorylation of tyrosine hydroxylase. The method for phosphorylation of 
human tyrosine hydroxylase was based on that developed for the rat enzyme (15). Each 
TyrH isoform (20 µM) was incubated with 60 µM ATP, 6 mM MgCl2, and 100 nM PKA 
catalytic subunit in 100 mM KCl, 10% glycerol, 50 mM HEPES, pH 7.0, at 4 ˚C. After 2 
hours, additional ATP, MgCl2 and PKA were added to yield final concentrations of 125 
µM, 12.5 mM, and 200 nM, respectively; the reaction was continued for 6 hours. The 
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phosphorylated enzyme was isolated on a MonoQ column using a gradient of 0-500 mM 
NaCl in the same buffer. The phosphorylation status was confirmed by incubating a 
sample of phosphorylated enzyme eluted from the MonoQ column with 15 mM MgCl2, 
88 nM PKA, 560 µM [γ-32P]ATP (1.97x105 cpm/nmol) in 10% glycerol, 50 mM 
HEPES, pH 7.0, at room temperature. Aliquots were removed at five minute intervals for 
15 minutes and spotted onto phosphocellulose filter paper; these were washed twice with 
75 mM phosphoric acid and once with acetone. The amount of radioactivity remaining 
on the filters was determined by scintillation counting. In all cases the previously 
phosphorylated enzymes incorporated less than 0.02 nmol phosphate/nmol TyrH; 
unphosphorylated enzyme incorporated a stoichiometric amount of phosphate under 
these conditions. 
Catecholamine binding. Catecholamine binding studies were performed by using 
previously described procedures (15). To determine the rate constants for dissociation of 
DOPA and dopamine, 40 µM unphosphorylated or phosphorylated TyrH was incubated 
with 60 µM DOPA or dopamine in 100 mM KCl, 10% glycerol, 50 mM HEPES, pH 7.0, 
at 10 ˚C. Formation of the enzyme-catecholamine complex was monitored by observing 
the increase in absorbance at 690 nm (43). After formation of the catecholamine 
complex was complete, 2,3-dihydroxynaphthalene (DHN) was added to give a final 
concentration of 1 mM; the increase in absorbance at 550 nm due to formation of the 
enzyme-DHN complex was then monitored. The dissociation rate constant was 
calculated by fitting the absorbance versus time to equation 1. 
At=A+ (A0-A) e-kt   (1) 
To determine association rate constants, 125 µM - 2 mM DOPA or dopamine 
was mixed with 15 µM (final concentrations) tyrosine hydroxylase in an Applied 
Photophysics SX-18MV stopped flow spectrophotometer. The increase in absorbance at 
690 nm was monitored and the resulting data fit to equation 1. 
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RESULTS 
Characterization of human tyrosine hydroxylase isoforms. Plasmids were 
constructed for expression of all four human TyrH isoforms in E. coli by starting with 
the cDNA for hTyrH2. All four proteins expressed well and could be purified using the 
protocol developed for the rat enzyme. The specific activities of the purified hTyrH 
isoforms were comparable: 1.8 µmol-min-1-mg-1 (hTyrH1), 1.2 µmol-min-1-mg-1 
(hTyrH2), 1.3 µmol-min-1-mg-1 (hTyrH3) and 1.5 µmol-min-1-mg-1 (hTyrH4). After 
incubation with a slight excess of ferrous ammonium sulfate and removal of excess iron, 
each isoform contained one atom of iron per monomer. The steady state kinetic 
parameters with tyrosine and 6MPH4 as substrates were measured for each isoform and 
are summarized in Table 2. The Vmax and Ktyr values are essentially the same among all 
four isoforms. The Km values for 6MPH4 for isoforms 2-4 are similar, while that for 
hTyrH1 is slightly larger.  
 
Table 2. Steady-State Kinetic Parameters of Human Tyrosine Hydroxylase 
Isoformsa. 
Enzyme Ktyr (µM)b K6MPH4 (µM)c Vmax (min-1) 
hTyrH1 77 ± 10 116 ± 10 135 ± 7 
hTyrH2 66 ± 5 75 ± 6 100 ± 2 
hTyrH3 79 ± 9 70 ± 9 119 ± 5 
hTyrH4 73 ± 6 63 ± 5 108 ± 3 
aConditions: 100 µg/ml catalase, 1 mM dithiothreitol, 10 µM ferrous ammonium sulfate, 
50 mM HEPES, pH 7.0, 32 ºC. b400 µM 6MPH4. c200 µM tyrosine. 
 
 
Catecholamine binding. Previous analyses of rat TyrH have shown that 
phosphorylation has a large effect on the binding of catecholamines to the ferric form of 
the enzyme (15). The rate constants for dissociation and association of DOPA and 
dopamine were determined for all four human isoforms by monitoring the formation of 
the broad charge-transfer absorbance band centered at 690 nm due to the complex. In the 
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case of complex formation, the rate constants were determined by mixing the enzyme 
with various concentrations of DOPA or dopamine (data not shown). The observed rate 
constants for binding derived from these analyses show a linear dependence on the 
concentration of DOPA or dopamine, as illustrated in Figure 6 for DOPA binding to 
unphosphorylated hTyrH1 and hTyrH4. This behavior is consistent with a simple 
bimolecular binding reaction. The second order rate constants for binding of DOPA or 
dopamine to each of the isoforms could be determined from the slopes of plots such as 
those in Figure 6. The resulting values are summarized in Tables 3 and 4. The values 
decrease slightly as one proceeds from isoform 1 to 4, with dopamine binding exhibiting 
slightly higher association rate constants overall than DOPA. 
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FIGURE 6. Concentration dependence of DOPA binding to hTyrH1 (filled circles) and 
hTyrH4 (open circles). 
 
While the rate constants for dissociation of catecholamines from TyrH can in 
principle be determined from the y-intercepts of plots such as those in Figure 6, the 
precision of the resulting values is low, especially in the case of dopamine. 
Consequently, the dissociation rate constants were measured directly. This was done by 
using DHN to displace the bound DOPA or dopamine, taking advantage of the spectral 
differences between the complexes with DHN, which exhibit maximal absorbance at 550 
nm, and those with catecholamines, with maximal absorbance at 690 nm. Each hTyrH 
isoform (30 µM) was incubated with 60 µM DOPA or dopamine until binding was 
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complete, as indicated by no further spectral changes. DHN was then added to give a 
final concentration of 1 mM; this concentration is sufficiently high that all of the 
catecholamine is displaced by the end of the reaction, and the binding of DHN is much 
more rapid than the dissociation of the catecholamine (15). Under these conditions, the 
rate constant for the formation of the DHN complex is equal to the rate constant for 
dissociation of the bound catecholamine. The spectral changes which occur when this is 
done with DOPA and the unphosphorylated enzymes are illustrated in Figure 7A for 
hTyrH4. DHN could similarly displace DOPA from the other isoforms. The first order 
rate constants for dissociation of DOPA from the unphosphorylated isoforms determined 
in this fashion are summarized in Table 3.  
In contrast to the results with DOPA, with dopamine there was no evidence for 
significant displacement of dopamine by DHN from any of the unphosphorylated 
isoforms, even after 12 h. There was a slight increase in absorbance at 550 nm, but no 
accompanying decrease at long wavelength (Figure 7B). At times longer than 12 hours 
significant protein precipitation was seen. As a result it was not possible to determine the 
rate constant for dissociation of dopamine from any of the unphosphorylated isoforms. If 
one assumes that the absorbance change seen in Figure 7B is completely due to 
replacement of dopamine by DHN and that the spectral changes are identical to those 
seen with the phosphorylated enzyme (Figure 7C), less than 10% of the dopamine is 
displaced by DHN after 12 h in the experiment illustrated in Figure 7B. This places an 
upper limit on the dissociation rate constant of 0.00015 min-1.  
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FIGURE 7. Spectral changes during displacement by DHN of DOPA (A) or dopamine 
(B and C) from unphosphorylated (A and B) and phosphorylated (C) hTyrH4. Enzyme 
(30 µM) was incubated with 60 µM L-DOPA or dopamine for 15 min in 10% glycerol, 
100 mM KCl, and 0.2 mM DTPA, 50 mM HEPES, pH 7, at 10 ºC, before the spectra 
indicated by solid lines were taken. DHN was then added to give a final concentration of 
1 mM; the spectra indicated by dashed lines were taken after 2.8 h (A) or 12.5 h (B and 
C). 
 
Effect of phosphorylation by protein kinase A on catecholamine binding to 
human TyrH. Each of the TyrH isoforms was phosphorylated with PKA, which is 
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specific for the serine corresponding to Ser40 of hTyrH1, followed by anion exchange 
chromatography to remove components of the phosphorylation reaction. When 
[γ32P]ATP was used for the reaction, all four hTyrH isoforms were found to be 
phosphorylated to 0.9 ± 0.2 mol phosphate /mol of enzyme. In addition, no further 
phosphate could be incorporated into the phosphorylated enzymes by further treatment 
with PKA and ATP, consistent with stoichiometric phosphorylation. Using the 
phosphorylated isoforms, the binding and dissociation rate constants for DOPA and 
dopamine were determined as described above for the unphosphorylated enzymes; the 
results are summarized in Tables 3 and 4 and illustrated in Figure 8. In the case of 
DOPA binding, phosphorylation increases the dissociation rate constant by 2.5 to 5-fold 
and increases the association rate constant by 3 to 4-fold. The increase in the association 
rate constant is comparable for each isoform, although the absolute magnitude of the 
value decreases as the size of the regulatory domain increases from hTyrH1 to hTyrH4. 
As a result of the comparable increases in the association and dissociation rate constants, 
the change in the Kd value for DOPA varies from an increase of slightly less than two-
fold for hTyrH1 to no effect for hTyrH4. Table 3 also shows the much larger increase 
seen with the rat enzyme (99). 
In contrast to the very small effect of phosphorylation on the affinity of the 
human isoforms for DOPA, there is a large effect on the binding of dopamine (Table 4). 
As was the case with DOPA, phosphorylation increases the association rate constants for 
all four isoforms by 3 to 4-fold. While no significant displacement of dopamine from the 
unphosphorylated enzyme could be seen upon incubation with DHN after 12 h, DHN 
was able to completely displace dopamine from the phosphorylated enzymes over the 
same time period (Figure 7C). This reflects an increase of at least two orders of 
magnitude in the dissociation rate constants for dopamine upon phosphorylation. Again, 
the effect decreases as one progresses from hTyrH1 to hTyrH4. The Kd values for 
dopamine binding to all four phosphorylated human isoforms are comparable to that for 
the rat enzyme (99). 
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Table 3. Kinetic Parameters for DOPA Binding to hTyrH Isoforms. 
Unphosphorylated enzyme 
isoform kona 
(mM-1 min-1)
 
koffb 
(min-1) 
Kdc 
(µM)
 
hTyrH1 18.6 ± 0.6 0.082 ± 0.001 4.45 ± 0.16 
hTyrH2 17.4 ± 1.2 0.078 ± 0.001 4.52 ± 0.32 
hTyrH3 10.8 ± 0.6 0.034 ± 0.001 3.17 ± 0.21 
hTyrH4 14.4 ± 1.2 0.060 ± 0.001 4.21 ± 0.36 
rTyrHd 39.0 ± 3.6 0.102 ± 0.006 2.70 ± 0.29 
Phosphorylated enzyme 
hTyrH1 61.2 ± 2.4 0.453 ± 0.012 7.41 ± 0.36 
hTyrH2 51.6 ± 3.0 0.334 ± 0.005 6.48 ± 0.40 
hTyrH3 40.2 ± 1.8 0.235 ± 0.015 5.87 ± 0.47 
hTyrH4 35.4 ± 1.2 0.142 ± 0.002 4.02 ± 0.16 
rTyrHd 66.0 ± 4.8 2.76 ± 0.54 41.7 ± 13.9 
aConditions: 10% glycerol, 100 mM KCl, 50 mM HEPES, pH 7, 10 ºC. bConditions: 1 
mM DHN, 60 µm DOPA, 10% glycerol, 100 mM KCl, 0.2 mM DTPA, 50 mM HEPES, 
pH 7, 10 ºC. cCalculated from the corresponding kon and koff values. dFrom McCulloch et 
al. 2001, determined at 15 ºC. 
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FIGURE 8. Effects of phosphorylation on the rate constants for association (A) and 
dissociation (B) of DOPA from TyrH isoforms. The conditions were as described for 
Figure 7. 
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Table 4. Kinetic Parameters for Dopamine Binding to hTyrH Isoforms. 
 Unphosphorylated enzyme 
isoform kona  
(mM-1 min-1) 
koffb 
(min-1) 
Kd  
(nM) 
hTyrH1 66.6 ± 3.0 < 0.00015 < 2.2 
hTyrH2 43.2 ± 2.4 < 0.00015 < 3.5 
hTyrH3 48.6 ± 2.4 < 0.00015 < 3.1 
hTyrH4 55.2 ± 1.8 < 0.00015 < 2.7 
rTyrHd 312 ± 18 0.000041 ± 0.000004 0.13 ± 0.02 
 Phosphorylated enzyme 
hTyrH1 172 ± 7 0.024 ± 0.002 143 ± 15 
hTyrH2 198 ± 7 0.016 ± 0.001 82 ± 4 
hTyrH3 148 ± 7 0.012 ± 0.001 85 ± 9 
hTyrH4 145 ± 4 0.011 ± 0.001 78 ± 4 
rTyrHd 474 ± 2 0.10 ± 0.002 208 ± 20 
aConditions: 10% glycerol, 100 mM KCl, 50 mM HEPES, pH 7, 10 ºC. bConditions: 1 
mM DHN, 60 µm dopamine, 10% glycerol, 100 mM KCl, 0.2 mM DTPA, 50 mM 
HEPES, pH 7, 10 ºC. dFrom reference (McCulloch et al. 2001); determined at 15 ºC. 
 
DISCUSSION 
The results presented here establish that phosphorylation of human TyrH 
decreases the affinity of the ferric enzyme for catecholamines and thereby extend the 
regulatory model developed for the rat enzyme. Still, the human and rat enzymes do 
show qualitative differences in their regulatory properties, and the four isoforms of 
human TyrH differ quantitatively in the effects of PKA phosphorylation.  
The steady state kinetic parameters of the four human isoforms reported here do 
not differ substantially from one another, indicating that the different insertions after 
Met30 of hTyrH do not markedly affect catalysis. The Vmax values for the different 
isoforms are comparable and are similar to that of the rat enzyme (52), while hTyrH1 has 
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a slightly higher Km value for 6MPH4 than the other three isoforms. A similar difference 
in Km values has been reported using tetrahydrobiopterin as substrate for the human 
isoforms (90). However, when the latter pterin is used, there is substantial substrate 
inhibition (90); this precludes measurement of actual Vmax values with the physiological 
substrate, a problem not encountered with 6MPH4. 
Phosphorylation by PKA of Ser40 in the regulatory domain of rat TyrH greatly 
decreases the affinity of that enzyme for catecholamines (15, 91). The largest effect is on 
the affinities for dopamine, norepinephrine, and epinephrine, with a smaller effect on the 
affinity for the product of the TyrH reaction, DOPA. There is no structure available for 
the regulatory domain of TyrH from any source which would provide insight into the 
structural basis for this effect. However, there is evidence that phosphorylation alters the 
structure of the regulatory domain and the interaction between the regulatory and 
catalytic domains. Phosphorylation increases the sensitivity to trypsin of the residues 
surrounding Ser40 in the rat enzyme, while dopamine has the opposite effect (77), 
demonstrating that the conformation of this region is sensitive to the regulatory status of 
the enzyme. The effect of dopamine, which binds in the active site (100, 101), on the 
conformation of the regulatory domain suggests that this region of the regulatory domain 
is close to the active site. The structure of the combined regulatory and catalytic domains 
of the related enzyme phenylalanine hydroxylase (16), which shows that the N-terminus 
of the regulatory domain physically blocks the active site, supports such a model. The 
insertions found in hTyrH2, hTyrH3 and hTyrH4 are after Met30 and thus immediately 
precede the phosphorylation sensitive region, providing a link between the structural 
differences among the human isoforms and any differences in their response to 
phosphorylation.  
Clearly, dopamine binds very tightly to all four human isoforms. In the case of 
the unphosphorylated enzyme, dopamine binding is effectively irreversible. For all four 
isoforms, phosphorylation results in an increase in the rate constants for dopamine 
dissociation of at least two orders of magnitude, with much smaller increases in the rate 
constants for association. Qualitatively this resembles the effects of phosphorylation of 
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the rat enzyme, demonstrating that the regulatory model developed with rat TyrH 
(Scheme 4) also applies to the human isoforms. In addition, there are quantitative 
differences in the binding of dopamine to the different phosphorylated isoforms. There is 
a small decrease in the association rate constant as one progresses from hTyrH1 to 
hTyrH4 for both the unphosphorylated and phosphorylated enzymes. A more significant 
effect is seen on the dissociation rate constants for the phosphorylated enzymes, which 
decrease as the size of the insertion after Met30 increases. As a result of these two 
trends, phosphorylated hTyrH1 has a significantly lower affinity for dopamine than the 
other three isoforms. Whether the same trend is seen with the unphosphorylated enzyme 
cannot be determined from the present data, although the results with DOPA (vide infra) 
suggest that this is indeed the case. However, the data do establish that the effect of 
phosphorylation on dopamine binding is attenuated by the insertions. 
The effects of phosphorylation on binding of DOPA to the human isoforms differ 
significantly from the effects on the binding of dopamine. The DOPA association and 
dissociation rate constants both decrease slightly as the size of the insertion increases 
from hTyrH1 to hTyrH4, resulting in the Kd values for DOPA binding to the 
unphosphorylated enzymes being essentially identical for all four isoforms and close to 
the value for the rat enzyme. However, phosphorylation by PKA has little to no effect on 
the affinity of human TyrH for DOPA. The association rate constants for all four 
isoforms increase about 4-fold upon phosphorylation; this is greater than the increase 
seen with the rat enzyme (15), but comparable to the change in the association rate 
constants for dopamine binding to the human enzymes. The increases upon 
phosphorylation in the rate constants for DOPA dissociation from the human isoforms 
are much less than is seen for rat TyrH. As was the case for dopamine binding, the 
insertions attenuate the effects of phosphorylation, in that both the association and 
dissociation rate constants for DOPA show smaller increases upon phosphorylation as 
the size of the insertion increases. Because both rate constants increase by comparable 
amounts, the Kd values increase less than two-fold when hTyrH1 is phosphorylated. The 
effect of phosphorylation on the Kd value decreases as the size of the insertion increases, 
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to the point where the value for hTyrH4 shows no change upon phosphorylation. In 
contrast, upon phosphorylation of rat TyrH the Kd value for DOPA increases about 20-
fold.  
The lack of a substantial change in the affinity of hTyrH for DOPA upon 
phosphorylation suggests that inhibition of the human enzyme by DOPA is not 
important for regulation in vivo while inhibition by dopamine is. This observation would 
be consistent with physiological levels of the two inhibitors. The concentration of DOPA 
in brain and adrenal tissues is quite low, well below 1 µM, due to its rapid conversion to 
dopamine by DOPA decarboxylase (102-105). Thus, the Kd for DOPA for even 
unphosphorylated hTyrH is likely to be much higher than the physiological 
concentration. This suggests that even unphosphorylated TyrH is not significantly 
inhibited by DOPA in the cell. In contrast, the average concentration of dopamine in 
brain and adrenal tissue is 5-10 µM (102, 104, 105); the concentration in the cytosol is 
undoubtedly much lower, since most of the dopamine is inside secretory vesicles (106-
108). The much lower Kd value for dopamine for the phosphorylated isoforms is 
consistent with the much lower level of catecholamines in the cytosol. Moreover, when 
TyrH is isolated from bovine adrenal or rat pheochromocytoma cells, the enzyme has a 
combination of dopamine, epinephrine, and norepinephrine bound, but no DOPA (92, 
93). This lack of DOPA in enzyme isolated from physiological sources is consistent with 
it not being a physiologically important inhibitor. 
In conclusion, the data presented here show that the regulatory model developed 
for rat TyrH also applies to all four human isoforms. The human isoforms differ from the 
rat enzyme in the lack of an effect of phosphorylation on DOPA binding. In addition, the 
insertions in the regulatory domain which differentiate the four human isoforms do 
affect their regulatory properties. 
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CHAPTER III 
MONITORING THE MOVEMENT OF THE LOOP RESIDUES 175-200 IN RAT 
TYROSINE HYDROXYLASE BY FLUORESCENCE ANISOTROPY 
 
INTRODUCTION 
TyrH catalyses the rate-limiting step in catecholamine synthesis, the 
hydroxylation of tyrosine to form DOPA with concomitant oxidation of pterin using 
molecular oxygen (81). The crystal structures of complexes of the homologous enzyme 
phenylalanine hydroxylase (PheH) with tetrahydrobiopterin and with both 
tetrahydrobiopterin and 3-(2-thienyl)-alanine show a large movement of a surface loop 
(residues 131-155) at the active site opening upon amino acid binding (Figure 9) (22). So 
far only two crystal structures for rTyrH are known; one with no ligands (17) and one 
with bound 7,8-dihydrobiopterin (18). The overall structure of catalytic domain does not 
change upon pterin binding. The loop region can be identifiable with missing residues 
between 182 and 186. There is no structure of TyrH or PheH with only an amino acid 
bound. The ternary structure of PheH shows a large conformational change in the 
surface loop upon binding of amino with most the moved residue being Tyr138 (Figure 
9B). This opens the question of whether a conformational change in the TyrH 
residues175-200 corresponds to the movement of PheH loop residues 131-155 (Figure 
9A and 10). Alanine scanning mutagenesis of these loop residues in TyrH shows that the 
K6MePH4 value does not change, whereas Ktyr and DOPA formation decrease and 
coupling between pterin oxidation and amino acid hydroxylation also decreases towards 
the center of loop. These results indicate that the loop plays an important role in DOPA 
formation (Daubner-unpublished observations). In the present study, steady-state and 
frequency-domain time-resolved fluorescence anisotropy spectroscopy were used to 
monitor movement of the loop in TyrH upon ligand binding.  
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FIGURE 9. (A) The structures of hPheH with BH4 bound (from PDB file 1J8U-green), 
hPheH with both BH4 and thienylalanine bound (from PDB file 1KW0-yellow) and of 
rTyrH with 7,8-BH2 bound (from PDB file 2TOH-blue) with loops shown in pink. (B) 
The movement of the 130-150 loop in PheH when an amino acid is bound. 
 
 
TyrH  CHHLVTKFDPDLDLDHPGFSDQVYRQR 
PheH  FANQILSYGAELDADHPGFKDPVYRAR 
FIGURE 10. Sequence alignment of PheH residues (131-155) and TyrH residues (177-
203) loop regions. 
 
EXPERIMENTAL PROCEDURES 
Materials. Custom oligonucleotides were obtained from Integrated DNA 
Technologies (Coralville, IA). Restriction endonucleases were from New England 
Biolabs Inc (Beverly, MA). Pfu DNA polymerase was obtained from Stratagene USA 
(La Jolla, CA). DNA sequencing was performed using the BigDye kit of ABI (Foster 
City, CA). 6-Methyltetrahydropterin (6MePH4) were purchased from B. Schircks 
Laboratories (Jona, Switzerland). Leupeptin and pepstatin were obtained from Peptides 
International (Louisville, KY). Catalase was obtained from Roche (Gaithersburg, MD). 
Distilled glycerol was from Invitrogen (Carlsbad, CA). 6-Methyl-5-
Tyr138 
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deazatetrahydropterin was synthesized essentially as described by Moad et al. (109) by 
Dr. Vijay Gawandi of Texas A&M University. All other reagents were commercially 
available. 
Cloning and characterization of tryptophan mutants. The three tryptophan 
residues at positions 166, 233, and 372 of rat TyrH were mutated sequentially to 
phenylalanine using the oligonucleotides in Table 5 using the Quick-Change protocol. In 
addition, Phe184 was mutated to tryptophan. These mutants were expressed in E. coli 
BL21 Star (DE3) cells as previously described for wild type TyrH (76); an AKTA FPLC 
with a 5 ml Hitrap-Heparin column was used in place of the Heparin-Sepharose column. 
The protein was dialyzed against 50 mM HEPES, pH 7.0, 10% glycerol and 75 µM 
diethylenetriaminepentaacetic acid (DTPA) prior to being loaded onto the Hitrap-
Heparin column; this was eluted with a linear gradient of 0-0.8 M NaCl in 75 µM 
DTPA, 10% glycerol, 50 mM HEPES, pH 7.0. Fractions containing tyrosine 
hydroxylase were pooled and precipitated by making the solution 65% saturated in 
ammonium sulfate. The pellet was resuspended in 100 mM KCl, 10% glycerol, 1 µM 
pepstatin, 1 µM leupeptin, 50 mM HEPES, pH 7.0 to give a concentration of ~300 µM 
TyrH. To this, ferrous ammonium sulfate was added to give a 20% molar excess of iron 
over TyrH active sites; excess iron was removed by dialysis (91). All protein purification 
steps were carried out at 4 ºC. Purified enzymes were stored at -80 ˚C. To obtain 
apoenzyme, the 65% ammonium sulfate pellet was dissolved in the same buffer 
containing 1 mM EDTA and incubated on ice for 30 minutes. The enzyme was then 
dialyzed against the same buffer to remove excess EDTA. The final stoichiometry of 
iron:enzyme was determined by atomic absorption  spectroscopy on a Perkin Elmer 
AAnalyst. All the enzymes used in this study contained 0.9-1.2 equivalents of iron in the 
holoenzyme or less than 0.2 equivalents in the apoenzyme. 
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Table 5. Oligonucleotides Used for Construction of Expression Plasmids for 
Tryptophan Mutants. 
Mutation Plus strand Minus strand 
W166F 5’-CAAGGTCCCCTTTTTCCC 
GCGGAAAGTG-3’ 
5’-CACTTTCCGCGGGAAAAA 
GGGGACCTTG-3’ 
F184W 5’-CCTGGTCACCAAGTGGG 
ACCCTGATCTGG-3’ 
5’-CCAGATCAGGGTCCCACT 
TGGTGACCAGG-3’ 
W233F 5’-GGAAGAGATTGCTACCT 
TTAAGGAGGTATATGTCAC 
GC-3’ 
5’-GCGTGACATATACCTCCT 
TAAAGGTAGCAATCTCTTC 
C-3’ 
W372F 5’-CCACGGTGTACTTTTTCA 
CTGTGG-3’ 
5’-CCACAGTGAAAAAGTACA 
CCGTGG-3’ 
 
Enzyme assays: A colorimetric end point assay for DOPA formation was used to 
measure tyrosine hydroxylase activity (52). Standard conditions were 0.5 µM enzyme, 
400 µM 6MePH4 and 100 µM tyrosine in 50 mM HEPES, pH 7.0, 100 µg/ml catalase, 1 
mM dithiothreitol, 10 µM ferrous ammonium sulfate, at 25 ºC. For determination of the 
Km value for tyrosine, assays contained 400 µM 6MePH4 and 10 to 360 µM tyrosine. For 
determination of the Km value for 6MePH4, assays contained 100 µM tyrosine and 10 to 
360 µM 6MePH4. To obtain the kinetic parameters in Table 6, the kinetic data were fit to 
the Michaelis-Menten equation using the program KaleidaGraph (Synergy Software).  
Inhibition data obtained by 6M5DPH4 were fit to the competitive inhibitor equation 
using Igor Pro program (WaveMatrics, Inc.). 
Rates of formation of tyrosine from phenylalanine were measured by monitoring 
the increase in absorbance at 275 nm (26, 110). The conditions were 0.4 µM enzyme, 
200 µM 6MePH4, 25 mM EPPS, pH 7.0, 60 µg/ml catalase, 10 µM ferrous ammonium 
sulfates and 5mM DTT. Rates of pterin oxidation were measured in the presence of 
phenylalanine as substrate for W166F/F184W/W233F/W372F TyrH by a coupled assay 
with dihydropteridine reductase, monitoring the decrease in absorbance at 340 nm due to 
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NADH oxidation. The background rate due to auto oxidation of the tetrahydropterin was 
subtracted when calculating the rate of the enzymatic reaction.  Conditions were 0.4 µM 
enzyme, 400 µM 6MePH4, 100 µg/ml catalase, 25 mM EPPS, pH 7.0, 10 µM ferrous 
ammonium sulfate, 0.2 mM NADH, 0.25 units/mL sheep dihydropteridine reductase 
(DHPR) at 25˚C  with varying concentration of phenylalanine from 0.5-12.6 mM. 
Steady-state fluorescence intensity and anisotropy. Steady-state fluorescence 
intensity and anisotropy were measured on an ISS Koala Model fluorometer equipped 
with a xenon arc lamp. Light of 300 nm wavelength was selected from the source by a 
monochromator and passed through a 0.5 mm slit and a Glan Thompson vertical 
polarizer. The emitted fluorescence between 310 and 500 nm wavelength range was 
collected through a 1.0 mm slit. For anisotropy measurements, emission intensities were 
collected through a 2 mm thick Schott WG345 cut-on filter and a Glan Thompson 
polarizer. The intensity from the samples upon addition of 6M5DPH4 was corrected with 
a factor for the inner filter effect, obtained by titrating 6M5DPH4 against N-acetyl-L-
tryptophanamide (NATA). NATA is an analogue for tryptophan in protein. All 
fluorescence studies were performed in 25 mM EPPS, pH 7.0, with a blank correction of 
the buffer. A W166F/F184W/W233F/W372F TyrH concentration of 3 µM was used for 
all steady-state fluorescence measurements. 
Frequency-domain lifetime and anisotropy measurements.  Frequency-domain 
measurements were performed on an ISS K2 multifrequency fluorometer equipped with 
digital acquisition electronics and fast Fourier transform data processing capability. The 
excitation beam of a 300 nm line from a Spectra Physics model argon ion laser was 
selected by passing through a Melles Griot-FIU004 filter which removes the 275 nm line 
produced by a deep-UV mode. The 300 nm line from the laser is always vertically 
polarized. Samples of 12 µM W166F/F184W/W233F/W372F TyrH in 25 mM EPPS, pH 
7.0 were excited by the 300 nm modulated line and the modulated emission was passed 
through Glan Thompson polarizer.  The ligands were dissolved in the same buffer. For 
lifetime measurements, emission was observed through the polarizer oriented at 54.7° to 
the vertical axis to avoid polarization artifacts. Phase shift and modulation data for each 
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sample with reference to NATA were obtained at each frequency of excitation. NATA 
with a lifetime of 2.85 ns in 0.1 M phosphate buffer, pH.7, was used as a reference 
sample. For frequency-domain anisotropy measurements, the emission was observed 
through the polarizer which is rotated between parallel and perpendicular orientation. 
The differential phase shift was obtained from the difference between the perpendicular 
and parallel components of the emission, and the modulation ratio was obtained from the 
ratio of the parallel to the perpendicular components of the modulated emission.  Data 
analysis of lifetime measurements was performed by fitting the data to a Gaussian 
distribution of lifetimes (equation 11) using Globals Unlimited software from the 
Laboratory for Fluorescence Dynamics, University of Illinois. The differential phase 
angle and modulation ratio data obtained frequency-domain experiment, were fit to a 
model described by equation 9 for a hindered local rotation with a slow global rotation 
using same software.  
General principles of fluorescence anisotropy. Anisotropy represents a means to 
monitor rotations of macromolecules in solution using the intrinsic fluorescence of the 
macromolecule itself or the extrinsic fluorescence of an attached probe. Anisotropy is 
the ratio of the polarized component to the total intensity (equation 2). It is measured by 
exciting a sample with vertically polarized light and measuring the subsequent emission 
through a polarizer oriented either parallel to the direction of polarized excitation (I) or 
perpendicular to the direction of polarized excitation (I

). Anisotropy (r) is expressed by 
equation 2. 
II2II
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r II
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         (2) 
For a fluorophore which is immobile during the lifetime of its excited state, the 
anisotropy r0 is given by equation 3. Here  is angle between absorption and emission 
dipoles. Anisotropy measured from fluorescence is between 0.4 and -0.2 because of 
photoselection upon excitation, non parallel absorption-emission dipoles and rotation of 
the molecule during the lifetime of excited state. Rotation of a fluorophore, resulting 
either from global movements of the macromolecule to which it is attached or to local 
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motions at the point of attachment, will lead to depolarization subsequent to absorption, 
as described by the Perrin equation  4 (111). Here r0 is the anisotropy in the absence of 
rotational diffusion,  is the lifetime of the fluorophore, and  is the correlation time for 
the diffusion process in the steady-state, an average of global and local rotational 
correlation times. Rotational correlation times for a hypothetical spherical protein may 
be related to physical constants as by equation 5 (111, 112). Here,  is the viscosity of 
the solution, k is the Boltzman constant, T is absolute temperature and V is the volume 
of the rotating unit. 
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General principle of frequency-domain measurements of lifetime. In order to 
determine explicitly fluorescence decay rates, time-resolved techniques must be used 
rather than the steady-state measurements described above. For time resolved 
anisotropy, there are two methods: i) time-domain and ii) frequency-domain. The time-
domain, pulse or impulse response method involves exciting a sample with a short burst 
of vertically polarized light and measuring the subsequent decay of fluorescence 
intensity along parallel and perpendicular orientations. Here, only frequency-domain will 
be discussed. The frequency-domain, phase-modulation or harmonic response approach 
involves a sample which is continuously excited by vertically polarized light whose 
intensity is modulated sinusoidally at an angular frequency . Because of the lag time 
between absorption and emission, the emission with the same frequency is delayed in 
time relative to excitation, resulting in a phase shift and demodulated emission. The 
phase shift is the fraction of a complete cycle elapsed as measured from an excitation 
reference point and often expressed as an angle. Modulation is the ratio of the amplitude 
of an emission wave to an excitation wave. With increasing modulation frequency of 
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excitation, the phase shift increases from 0° to 90° and the modulation decreases from 
1.0 to 0.0. The relationship at each frequency between the phase shift () and the 
modulation ratio (m) and lifetime () is given by equations 6 and 7 (113). Here,  and 
m are the lifetimes calculated from the phase shift and from the modulation ratio, 
respectively.  and m  will only be equal to each other and invariant with frequency if 
the sample is homogeneous (113). Even though the equations help in calculating 
lifetimes directly, usually lifetime measurements are done by measuring the phase shift 
and modulation with reference to a sample of known lifetime. Data from the sample and 
from the reference are collected at several frequencies of excitation. At each frequency, 
the extent of demodulation and the phase shift produced by the sample of unknown 
lifetime are measured. This can allow the modeling of more complex emission 
mechanism the might give rise to multiple exponential decays or distributions of many 
closely spaced lifetimes.  
φωτφ =tan    (6) 
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m
m
τω+
=   (7) 
General principle of frequency-domain measurements of dynamic anisotropy. 
Dynamic anisotropy or differential polarization can be determined by phase-modulation 
fluorometry. The differential phase shift of perpendicular and parallel components of 
emission and demodulation ratio of the parallel to perpendicular components of emission 
from a sample are measured subsequent to excitation with polarized sinusoidally-
modulated light (114, 115). The primary advantage of dynamic anisotropy over the 
steady-state method is the ability to separate and quantify the different modes of rotation 
(equation 8). Because of the complex nature of the equations describing the response of 
differential phase and modulation to variations in rotational characteristics, simulations 
are typically performed. For example, a tryptophan on a protein may posses rotational 
characteristics deriving from the motion of the protein as a whole as well as faster 
motions associated with the side chain itself (116, 117). The rate of anisotropy decay is 
given by equation 9. Here r0 is the anisotropy at time t = 0, r is the anisotropy that 
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persists at times long relative to the short correlation time, 1. 2 is the rotational 
correlation time for the slower global rotation, and 1 is the rotational correlation time 
for the hindered local rotation. Therefore, dynamic anisotropy measurements when 
performed at multiple frequencies not only have the capability of assigning separate 
rotational correlation times to each level of rotational motion, but also can differentiate 
at the local level between the amplitude and rates of rotation associated with the side 
chain. Changes in the amplitude of local motion, for example, are reflected as changes in 
r in equation 9, while changes in the rates of motion are represented by changes in 1. 
Steady-state measurements of anisotropy can present at best an average of all such 
processes. The amplitude of local motion may be described in terms of a cone angle of 
limited rotation () by equation 10. 
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RESULTS 
Cloning and characterization of tryptophan mutants. TyrH has tryptophans at 
positions 166, 233 and 372. To avoid the complications associated with fluorescence 
anisotropy measurements, these tryptophans were mutated to phenylalanine. The residue 
Phe184 in the center of loop was mutated to tryptophan to monitor the movement of 
loop. All mutant proteins expressed well in E. coli and could be purified using the 
protocol developed for the rat enzyme. After incubation with a slight excess of ferrous 
ammonium sulfate and removal of excess iron, each mutant contained one atom of iron 
per monomer. Apoenzyme contained less than 0.2 equivalent iron per monomer. The 
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steady state kinetic parameters with tyrosine and 6MePH4 as substrates were measured 
for all tryptophan mutants and are summarized in Table 6. In the case of W166F 
mutations, the K6MePH4 value increased 3 to 4 fold. In the cases of W372F and 
F184W/W372F TyrH the Ktyr value decreased 5 to 10 fold. Otherwise the kinetic 
parameters suggest that catalysis and binding are not significantly perturbed in these 
mutant proteins (Table 6).  
 
Table 6. Steady State Kinetic Parameters of TyrH Tryptophan Mutants.  
Enzyme 
Ktyr 
(µM)a 
K6MePH4 
(µM)b 
Vmax  
(min-1) 
WT rTyrH 80 ± 18 45 ± 4 182 ± 26 
W372F rTyrH 8 ± 1 45 ± 5 44 ± 3 
W166F/W372F rTyrH 90 ± 4 180 ± 18 243 ± 5 
W166F/W233F/W372F rTyrH 90 ± 6 162 ± 15 276 ± 7 
W166F/F184W/ W233F/W372F rTyrH 64 ± 6 116 ± 11 165 ± 5 
W166F/F184W/W372F rTyrH 65 ± 5 129 ± 4 184 ± 5 
F184W/W372F rTyrH 17 ± 5 31 ± 4 64 ± 6 
Conditions: 0.2 µM enzyme, 100 µg/ml catalase, 50 mM HEPES, pH 7.0, 10 µM ferrous 
ammonium sulfate, 1 mM DTT at 25˚C. a380 µM 6MePH4 with varied concentrations of 
tyrosine from 0-350 µM. b100 µM tyrosine with varied concentrations of 6MePH4 from 
0-350 µM 
 
 
Phenylalanine is a known substrate for TyrH (23). The steady state kinetics for 
tetrahydropterin oxidation and tyrosine formation by W166F/F184W/ W233F/W372F 
rTyrH were studied as described in Experimental Procedures. The data for 
tetrahydropterin oxidation were fit to the Michaelis-Menten equation to yield a Kphe 
value of 0.90 ± 0.04 mM and a Vmax value of 264 ± 4 min-1 (Figure 11A). A Kphe value 
of 0.90 ± 0.16 mM and a Vmax value of 55 ± 3 min-1 were obtained for tyrosine formation 
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(Figure 11B). These results indicate that only 20% of 6MePH4 oxidation was used for 
tyrosine formation. 
6M5DPH4 is an air stable analogue of the substrate 6MePH4 (Figure 12). 
Accordingly, the deazapterin was used to study binding to the pterin binding site (118). 
6M5DPH4 is a competitive inhibitor vs 6MePH4 with a Ki value of 140 ± 19 µM (Figure 
13). 
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FIGURE 11. Steady state kinetics of W166F/F184W/W233F/W372F rTyrH with 
phenylalanine as a substrate.  A) tetrahydropterin oxidation; B) tyrosine formation. 
Conditions were as described in Experimental Procedures. The lines are from fits to the 
Michaelis-Menten equation. 
 
C
H2
H
N
NH
N
H
H
H3C
H
O
NH2
 
FIGURE 12. 6-Methyl-5-deazatetrahydropterin (6M5DPH4). 
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FIGURE 13. Inhibition of W166F/F184W/W233F/W372F TyrH by 6M5DPH4. Initial 
rates were determined in the presence of no (), 50 µM (), 100 µM (), 200 µM (x), or 
400 µM (+) 6M5DPH4. The lines are from v = (VS)/( K(1 + I/Ks) +S). Conditions: 0.5 
µM  W166F/F184W/W233F/W372F TyrH, 25 µM EPPS pH 7.0, 0.2 mM NADH, 2.5 µl 
dihydropteridine reductase (, 100 µg catalase, 10 µM Fe(NH4)2SO4. 
 
Steady state fluorescence intensity. The intrinsic tryptophan fluorescence 
emission from the enzyme was determined in the presence and absence of ligands. The 
corrected intensity of W166F/F184W/W233F/W372F TyrH in the presence of either 
phenylalanine or 6M5DPH4 was not significantly different from that in the absence of 
these ligands (Figure 14). 
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FIGURE 14. Steady state fluorescence intensity of W166F/F184W/W233F/W372F 
rTyrH (FeIII) in 25 mM EPPS buffer, pH 7.0, at 25 ºC in the absence () and presence 
() of (A) 10 mM phenylalanine, (B) 500 µM 6M5DPH4, or (C) both ligands.  
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Steady-state fluorescence anisotropy of W166F/F184W/W233F/W372F TyrH in 
the presence of ligands. Steady-state fluorescence anisotropy is a measurement for the 
movement of an intrinsic fluorophore. The steady-state fluorescence anisotropy of the 
single tryptophan in the protein was measured by exciting the sample with plane 
polarized light of 300 nm oriented vertically and recording the emission intensity  
passing through an emission filter of Schott WG345 and Glan Thompson polarizer 
oriented vertical and horizontal to the excitation light. The average anisotropy of 
W166F/F184W/W233F/W372F TyrH with iron bound is 0.177 ± 0.001 in the absence of 
ligands. The steady state anisotropy experiments with the 6M5DPH4 were performed at 
500 µM to avoid an inner filter effect, although this concentration is not saturating. The 
anisotropy increases in the presence of either phenylalanine or 6M5DPH4 (Figure 15). A 
much larger increase in anisotropy is observed with 6M5DPH4 alone than with 
phenylalanine alone (Figure 15). The increase in anisotropy is concentration dependent 
for both phenylalanine and 6M5DPH4 (Figure 16). In case of phenylalanine, the 
observed anisotropy upon addition of 10 mM at a time is much than the anisotropy 
change upon titration. The Kd values determined from the anisotropy of 0.73 ± 0.30 mM 
for phenylalanine and 224 ± 44 µM for 6M5DPH4 are comparable to the steady-state 
kinetic Kphe and Ki values. The presence of phenylalanine results in a similar Kd value of 
190 ± 34 µM for 6M5DPH4 and an increase in anisotropy of 0.001 ± 0.003 (Figure 16C).  
Essentially all of the change in anisotropy of 0.015 ± 0.002 is observed with 6M5DPH4 
alone (Figure 15B and 17C).  
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FIGURE 15. Steady-state fluorescence anisotropy of W166F/F184W/W233F/W372F 
rTyrH (FeIII) in 25 mM EPPS buffer, pH 7, at 25 ºC: (A) in the absence (empty bars) 
and presence (filled bars) of 10 mM phenylalanine and 500 µM 6M5DPH4. (B) Change 
in anisotropy. 
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FIGURE 16. Steady-state fluorescence anisotropy of W166F/F184W/W233F/W372F 
rTyrH Fe(III) in 25 mM EPPS buffer, pH 7, at 25 ºC as a function of the concentration of 
(A) phenylalanine (), (B) 6M5DPH4 (), or (C) 6M5DPH4 in the presence of 10 mM 
phenylalanine (). 
 
The magnitude of the anisotropy change also depends on whether the enzyme 
contains iron (Figure 17). In case of the apoenzyme the average anisotropy was 0.1572 ± 
0.0008 whereas holoenzyme was 0.1768 ± 0.0009. Titration of the apoenzyme with 
ferric iron to make holoenzyme was not possible because of its insolubility. The addition 
of phenylalanine resulted in a decrease in the anisotropy of the apoenzyme. Addition of 
6M5DPH4 increased the anisotropy by 0.010 ± 0.002, while the presence of both ligands 
increased it somewhat less, to 0.007 ± 0.002 (Figure 17 A and B). These magnitudes 
were less than the increases seen with the holoenzyme (Figure 18). 
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FIGURE 17. Steady-state fluorescence anisotropy of W166F/F184W/W233F/W372F 
rTyrH (apo) in 25 mM EPPS buffer, pH 7, at 25 ºC: (A) in the absence (empty bars) and 
presence (filled bars) of 10 mM phenylalanine and 500 µM 6M5DPH4. (B) Change in 
anisotropy. 
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FIGURE 18. Comparison of the change in anisotropy of holo- and apoenzymes. Change 
in steady-state fluorescence anisotropy of W166F/F184W/W233F/W372F rTyrH (holo-
first bar and apo-second bar) in 25 mM EPPS buffer, pH 7, with 10 mM phenylalanine 
and 500 µM 6M5DPH4. 
 
Frequency-domain lifetime measurements. According to Perrin’s equation 4, a 
change in anisotropy could occur because of a change in the fluorescence lifetime and/or 
the rotational correlation time of the fluorophore. The frequency-domain method was 
used to characterize the changes in the characteristics of fluorescence emission as a 
function of the frequency of the modulated excitation. The emission polarizer was 
oriented at the magic angle to obtain a measured intensity proportional to the total 
intensity. The two observable characteristics of frequency domain data are phase shift 
and modulation. The phase shift and modulation of the samples at each frequency of 
excitation with reference to a known lifetime were obtained in the presence and absence 
of ligands (Figure 19).  To obtain lifetimes, the data were fit to a Gaussian distribution of 
lifetime () using equation 11, where C is the central lifetime and W is the width. The 
numerical results are summarized in Table 7. The lifetimes, around 4.1 to 4.4 ns change 
very little upon binding of the ligands. Therefore, the change in steady state anisotropy 
upon 6M5DPH4 binding is due to a change in the rotational characteristics of the sole 
tryptophan. 
( ) ( ) piτ τ 222 2/ Wef WC−−=    (11) 
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FIGURE 19. Phase shift (open) and modulation ratio (filled) with frequency for enzyme 
W166F/F184W/W233F/W372F rTyrH alone (circle), with phenylalanine (diamond), 
with 6M5DPH4 (triangle) and with both (inverted triangle). The lines represent the best 
fit of the data to a model describing a Gaussian distribution of lifetimes (equation 11). 
 
Table 7. Fluorescence Lifetimes of the Tryptophan in W166F/F184W/W233F/ 
W372F rTyrH. 
Ligands C (ns) W (ns) 
No ligand 4.47 ± 0.04 2.53 ± 0.06 
10 mM Phe 4.24 ± 0.04 2.81 ± 0.06 
500 µM 6M5DPH4 4.38  ± 0.04 2.90 ± 0.06 
500 µM 6M5DPH4 + 10 mM Phe 4.13 ± 0.05 3.01 ± 0.07 
Data were fit to equation 11. 
 
 
Frequency-domain anisotropy measurement. The different modes of rotation 
associated with a fluorescent moiety that is amplitude and rates of rotation can be 
identified and quantified by dynamic anisotropy or differential polarization; this is not 
possible with steady-state anisotropy measurements. Vertically polarized sinusoidally-
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modulated light was used to get differential phase that is difference between 
perpendicular and parallel phase component of emission and to get modulation ratio that 
is ratio of the parallel to perpendicular modulation component of emission from 
W166F/F184W/W233F/W372F rTyrH in the absence and presence of ligands (Figure 
20). The presence of a rapid motion is evident from the phase-angle distributions at the 
higher frequencies. A decreased amplitude of the rapid motion was observed in the 
presence of 6M5DPH4 while the presence of phenylalanine did not change the 
amplitude. The curves in Figure 20 represent the best fit of each data set to a model 
describing a hindered local motion plus a global rotation (equation 9) (116, 117). 
Hindered means the angular range of rotational motion is limited for the tryptophan and 
the anisotropy (r∞) does not decay to zero. r0 is anisotropy at time zero and is 
independent of the rotational motion, 1 and 2 are the rotational correlation times 
associated with the two modes of rotation with 1<< 2, and r∞ is the anisotropy that 
persists for a longer time relative to the short rotational correlation time, 1. 
Consequently, changes in the amplitude of local rotation are reflected as changes in r∞. 
When the data are analyzed independently, 1 and 2 changed very little. Lifetimes for 
data analysis were fixed with the values in Table 8 even though they were not 
significantly different. Using all of the data sets in the presence and absence of ligands, a 
Global analysis was performed in which 1 and 2 as well as r0 were linked. The values 
obtained for 1, 2 and r0 were found to be equal to 1.89 ± 0.25 ns, 115 ± 10 ns, and 0.22 
± 0.03, respectively. The preexponential amplitude of the local component (r0-r∞) was 
found to be 6M5DPH4 dependent. This data analysis of binding gave a 50% decrease in 
the preexponential amplitude in the case of 6M5DPH4 irrespective of phenylalanine 
(Table 8). With phenylalanine, the preexponential amplitude did not change from the 
enzyme alone. The calculated cone angle using the equation 10 is decreased by 1 degree 
in the presence of phenylalanine whereas the cone angle decreases about 5-6 degrees in 
the presence of 6M5DPH4, irrespective of whether phenylalanine is present (Table 8). 
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FIGURE 20. Frequency dependence of the differential phase (open) and modulation 
ratio (filled) of the tryptophan fluorescence of W166F/F184W/W233F/W372F rTyrH, 
for enzyme alone (circle), phenylalanine (diamond), 6M5DPH4 (triangle) and both 
(inverted triangle). The curves represent the best fit of the data to a model describing a 
hindered local motion plus a global rotation (equation 9). 
 
Table 8. Preexponential Amplitude and Cone Angle of Tryptophan. 
Ligands (r0-r∞)  (deg) 
No ligand 0.048 ± 0.014 24 ± 3 
10 mM Phe  0.041 ± 0.015 22 ± 2 
500 µM 6M5DPH4 0.027 ± 0.014 17 ± 2 
500 µM 6M5DPH4 + 10 mM Phe 0.028 ± 0.015 18 ± 2 
Data from differential polarization were fit to a model describing a hindered rotation 
with a slow global rotation equation 9. The cone angle () of local rotation for the 
tryptophan was obtained from equation 10. Here, (r0-r∞) is the preexponential amplitude 
for the fast rotation. 
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DISCUSSION 
The large conformational change in residues 132-148 of PheH when an amino 
acid substrate is bound (22) suggested that this movement is the conformational change 
required prior to chemistry in these enzymes. Fluorescence anisotropy can provide a 
sensitive probe of the dynamics of local regions of proteins if they contain a suitable 
fluorophore. For this study tryptophan was chosen as the fluorophore, since it is a natural 
component of proteins. To generate a suitable protein for analysis of the loop movement, 
it was necessary to introduce a tryptophan into the loop and remove the three native 
tryptophans. The similar kinetic characteristics of these mutant enzymes establishes that 
the four amino acid changes did not have a significant effect on catalysis of binding, 
beyond a small change in the Km value for the tetrahydropterin. Critically, the 
introduction of the larger tryptophan side chain in place of Phe184 was not problematic. 
The results described in this chapter establish that this mutant protein is suitable for 
study of the effects of ligands on the mobility of the active site loop. 
The steady-state fluorescence intensity of W166F/F184W/W233F/W372F rTyrH 
(FeIII) was unaffected by the binding of the ligands used here. This eliminates concerns 
that the changes in anisotropy are complicated by changes in intensity. It also rules out 
the use of fluorescence intensity measurements to analyze ligand binding in TyrH. The 
lack of a change in intensity suggests that the side chain of the tryptophan still has 
significant solvent exposure when both the amino acid and the pterin are bound. This is 
consistent with a modeling analysis of the effects of replacing Tyr138 in PheH with 
tryptophan, which showed that the edge of the indole ring would still be solvent exposed 
(results not shown). 
In contrast to the steady-state fluorescence, fluorescence anisotropy did detect 
conformational changes upon biding of ligands. In the case of phenylalanine, there was a 
very small change in the anisotropy within minutes of the addition of a saturating 
amount of phenylalanine. A larger change was seen during the titration, but this 
experiment required several hours. Apparently there is a very slow conformational 
change in the presence of phenylalanine; however, it is much too slow to be relevant to 
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catalysis. In contrast to the situation with the amino acid ligand, the change in anisotropy 
upon 6M5DPH4 binding was immediate. In addition, the change was not time-
dependent, in that the magnitude of the change in the anisotropy was the same whether 
500 µM 6M5DPH4 was added directly or during a slow titration. Consequently, this 
change can be considered relevant to catalysis. The magnitude of the anisotropy change 
seen in the presence of the pterin was much greater than that produced by phenylalanine. 
Moreover, the magnitude of the change with 6M5DPH4 was the same in the presence of 
phenylalanine. This indicates that 6M5DPH4 alone can decrease the loop mobility in 
TyrH. Further, the lack of a significant change in the lifetimes of the tryptophan 
fluorescence in the presence of ligands supports the conclusion that the increase in 
anisotropy by 6M5DPH4 is due to a decrease in the loop mobility.  
Iron at the active site of TyrH plays an important role in binding of ligands. The 
average anisotropy associated with the apoenzyme is less than that of the holoenzyme 
indicating that the protein is more flexible in the absence of iron. Even in the absence of 
iron in the active site, 6M5DPH4 decreased the mobility of the loop, suggesting that the 
loop movement upon pterin binding is not directly linked to the metal atom. In contrast 
to the results with the apoenzyme, the presence of the amino acid does affect the 
magnitude of the anisotropy change seen with the pterin. Thus the effects of binding the 
amino acid depend upon the presence of iron in the active site. While the structural basis 
for this is not clear, it does suggest that binding of the amino acid substrate is linked to 
changes in the iron site. 
The dynamic anisotropy experiments clearly confirmed that the presence of 
6M5DPH4 changes the environment and the dynamics of the tryptophan moiety in the 
loop. The rotational correlation time associated with the fast local motion of the loop 
was not changed in the presence of ligands. This was also the case with the correlation 
time associated with the global motion of the protein, but this would not be expected to 
be altered by the small increase in mass upon ligand binding unless there were very large 
changes in the overall protein conformation. In contrast, if binding of ligands were to 
eliminate a motion of the loop, there should be a large change in the corresponding 
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correlation time. Instead, there was a decrease in amplitude of the rotation associated 
with tryptophan in the loop upon binding of 6M5DPH4. This indicates that the extent of 
motion of the loop is reduced rather that the rate constant for the motion. The magnitude 
of this decrease could be modeled as a decrease in the cone angle of the local tryptophan 
side chain of about 5-6 degrees. Again, this only occurs in the presence of 6M5DPH4, 
irrespective of the presence of phenylalanine.  
Taken together, all of the fluorescence anisotropy experiment suggests that pterin 
binding alone is responsible for a conformational change in the active site loop. This is 
in contrast to the crystal structures of PheH which suggests that it is the binding of the 
amino acid to the binary tetrahydropterin-enzyme complex which causes the 
conformational change. However, the present results are consistent with both the steady-
sate kinetic mechanism of TyrH and the effects of alanine scanning mutagenesis of loop 
residues.  The steady-state kinetic mechanism of TyrH is ordered, with the 
tetrahydropterin binding before the amino acid (52). One explanation for such ordered 
kinetics is that the binding of the first substrate causes a conformational change 
necessary for proper formation of the binding site for the subsequent ligand. This model 
is fully consistent with the results presented here, in that fluorescence anisotropy 
measurements of the active site loop directly detects a conformational change in the loop 
upon binding pterin but not amino acid. The results of alanine-scanning mutagenesis 
were also interpreted as supporting a model in which pterin binding causes a change in 
the conformation of the loop which is required for proper binding of the amino acid 
substrate (119). Thus, while the results presented here may not be those anticipated from 
the PheH structures, they are fully consistent with solution studies of TyrH. 
In conclusion, the mutant form of TyrH containing a single tryptophan residue in 
the proposed mobile loop over the active site has proved to be a useful probe of 
structural changes upon binding of ligands. Binding of a pterin reduces the amplitude of 
the loop movement and makes a tight binding pocket for the amino acid. The results 
indicate that the overall decrease in loop mobility is due to 6M5DPH4 binding alone. 
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CHAPTER IV 
TYROSINE HYDROXYLASE DYNAMICS PROBED BY H/D EXCHANGE AND 
MASS SPECTROMETRY 
 
INTRODUCTION 
According to the PheH ternary structure, a large conformational change occurs in 
residues 131-155 upon amino acid binding to the BH4 complex. The fluorescence 
anisotropy experiments with mutant TyrH (FeIII) in chapter III suggest that this loop 
becomes less mobile upon binding of a pterin only. The functional iron in TyrH during 
catalysis is FeII (scheme 4). The known physiological reductant for iron to make FeIII to 
FeII is tetrahydrobiopterin ((80) in press 2006) (79). To understand the dynamics of wild 
type TyrH under physiological conditions an alternative method has been employed in 
which its natural substrates and also the FeII and FeIII states of TyrH can be 
investigated. This chapter will focus on the role of substrates on the conformational 
change of the loop in TyrH (FeIII) and TyrH (FeII), using H/D exchange mass 
spectrometry.  
H/D exchange mass spectrometry is a sensitive tool to understand conformational 
changes using exchange of protons on amide nitrogens with deuterium in D2O. The 
increase in the mass of the region due to deuteriums can be investigated by mass 
spectrometry of the fragmented protein. Probing hydrogen bonding and structural 
dynamics in proteins with hydrogen exchange was initiated by Lingerstrom-Lang nearly 
50 years ago (120). In recent years, the approach of H-D exchange coupled with NMR 
analysis has revealed detailed site-specific information on bond formation and changes 
in bond energetics as a function of folding, conformational change, or ligand binding. 
However, these methods are confined to a small (yet growing) subset of proteins that are 
amenable to NMR and crystallization analysis. Insights into larger protein systems are 
facilitated by region specific H-D exchange followed by proteolytic fragmentation and 
subsequent analysis by mass spectrometric techniques (121). 
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EXPERIMENTAL PROCEDURES 
Materials. 6MePH4 and BH4 was purchased from B. Schirks Laboratories. L-
Phenylalanine and L-tyrosine were purchased from Sigma Chemical Company. Protein 
& Peptide C18 218TP5215 was purchased from Vydac (Columbia, MI). 6M5DPH4 was 
synthesized according to Moad et al. (109) by Dr. Vijay Gawandi from TAMU. Pepsin 
A from porcine stomach was purchased form Worthington Biochemical Corporation. 
Methylamine hexamethylene methylamine NONOate was purchased from Cayman 
Chemicals.  
Protein expression and purification. rTyrH was expressed in E. coli BL21 Star 
(DE3) cells as previously described with the modifications described in chaper III (76). 
Purified enzyme was stored in 5 mM HEPES, pH 7.0, 100 mM KCl, 10% glycerol at -80 
˚C.  
Identification of peptic fragments of rTyrH. For sequencing of TyrH peptic 
fragments, HPLC-MS/MS analysis was performed using a LCQ DECA XP ion-trap 
mass spectrometer equipped with an electrospray ionization (ESI) source. Forty µg of 
rTyrH in 5 µl of 5 mM HEPES, pH 7.0, 100 mM KCl and 10% glycerol was diluted to 
100 µl with water at 25 °C. 20 µl of this was then mixed with 20 µl of 100 mM sodium 
citrate, pH 2.4, at 0 °C. An equal weight of pepsin (7.6 µg in 2.5 µl water) was added 
and the sample was left on ice for 5 minutes. The digested sample of 20 µl was then 
injected onto a reverse-phase HPLC column (2.1 mm X 150 mm) connected to a 
ThermoFinnigan Surveyor HPLC (San Jose CA). The buffers used were A) water with 
~0.1% formic acid, pH 2.4, and B) 100% acetonitrile with ~0.1% formic acid, pH 2.4. 
The column was washed with 2% of buffer B for 5 min by direct flow at a rate of 200 
µl/min. Peptides were separated by using a gradient of 20%-60% buffer B over 15 min at 
200 µl/min. The HPLC injection loop, all buffers and the column were immersed in an 
ice bath to mimic the H/D experiments. The mass spectrometer was set to detect the total 
intensity of the ions in the m/z range of 400-2000. Mass scanning was followed by 
collision-induced dissociation in positive mode to acquire a MS/MS spectrum on the 
most intense ion within a peak during the LC run. Angiotensin was used to optimize the 
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sheath, auxillary nitrogen gas pressures and tube lens voltage. The headed capillary was 
maintained at 150 °C, and spray voltage was kept at 3.0 kV. The detector was calibrated 
to unit resolution and the data were collected at a scan time of 1 second and a peak width 
of 0.5 by scanning 400-2000 m/z. The MS/MS spectra were interpreted with 
TurboSEQUEST software, a search tool from BioWorks (Thermo Finningan, Version 
3.1). TurboSEQUEST creates an experimental file of peptide masses (.dta files) from 
MS/MS experiments (.raw files) and correlates this with theoretical mass spectra 
produced from sequences generated from a protein fasta database.  The identities of the 
peptides from the experimental file were further confirmed from a peptic peptide map of 
TyrH generated with the program MS-digest by Peter Baker Instructions 
(http://prospector.ucsf.edu /ucsfhtml4.0/msdigest.htm).  
H/D exchange studies. HPLC/ESI-MS was used to determine the extent of 
deuterium incorporation into rTyrH (122). H/D exchange from solvent was initiated by 
dilution of 120 µg rTyrH in 15 µl of 5 mM HEPES, pH 7.0, 100 mM KCl, 10% glycerol 
into 300 µl of D2O (20 volumes) at 25 ºC. Stock solutions of 5.25 mM 6MePH4 and 1.05 
mM BH4 were made in anaerobic D2O to prevent autooxidation.  For reactions under 
anaerobic conditions, the solution containing enzyme and the solution containing the 
ligands were made anaerobic by alternately exposing to argon and vacuum. The ligand 
solution was then added to the enzyme solution with a syringe flushed with argon gas. In 
case of making complex of TyrH with FeII, equimolar concentrations of anaerobic 
ferrous ammonium sulfate was added to anaerobic apoenzyme and incubated on ice for 
10 min. In the case of nitric oxide, methylamine hexamethylene methylamine NONOate 
was dissolved in anaerobic D2O and exposed for a very short time to argon and vacuum 
to remove any oxygen before being mixed with the enzyme; after 2 min, tyrosine and 
BH4 were added to the enzyme-NO complex. At the indicated time intervals, a 20 µl 
sample was removed from the solution and mixed with an equal volume of 100 mM 
sodium citrate buffer, pH 2.4, at 0 ºC. Immediately, 2.5 µl pepsin in water (3.1 µg/µl) 
was added, and the sample was digested at 0 ºC for 5 min and then injected onto the 
HPLC column. HPLC conditions were the same as above. The buffers, loop and column 
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were immersed in an ice bath to minimize D/H exchange with HPLC solvents during 
chromatography. LC-MS analysis of the HPLC effluent was done to determine the 
extent of deuterium incorporation into rTyrH.  
Calculation of the deuterium labeling distribution. The isotope pattern of the 
loop fragment formed by a mixture of ions with different amounts of deuterium was 
identified from the total ion chromatograph using Qual Browser software. MagTran 1.0 
beta 9 software (123) was used to determine the centroid of the extracted composite 
isotope envelope. The number of amide hydrogens exchanged at a given time was 
determined by fitting the data to equation 12 using KaleidaGraph (Synergy software). 
Here, D is the number of deuterium atoms present in a peptide, N is the number of 
peptide amide linkages in a segment, and ki is the hydrogen-deuterium exchange rate 
constant for each peptide linkage. 

=
−
−=
N
i
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1
  (12) 
General principle of H/D exchange mass spectrometry. Hydrogen-deuterium 
(H/D) exchange is a popular and sensitive method for elucidation of protein structural 
changes. Phenomenologically, the method is based on the H/D exchange of amide 
protons located at the peptide backbone participating in intramolecular hydrogen 
bonding because these are the slowest to exchange and thus the most easily detected by 
experiments. The method was introduced by Linderstrom-Lang to study protein 
dynamics (120). In 1993, Zhang and Smith were the first to combine H/D exchange with 
mass spectrometry to improve the spatial resolution by proteolysis and mass analysis of 
the peptide fragments (124). Since then H/D exchange has emerged as an essential tool 
to study protein structure in solution. From this method one can obtain information on 
protein-protein and protein-ligand interactions and on conformational changes in protein 
with a resolution of 1-10 residues (120). The advantages of this technique are the lack of 
size limitation to the protein, working protein concentrations in the sub-micromolar 
range, and its applicability to membrane proteins (124). 
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Theoretically, the exchange of an amide hydrogen is a chemical exchange with 
solvent where base catalyses the proton abstraction at neutral pH (125). The intrinsic rate 
of exchange of an exposed proton is on the order of 10 s-1. The exchange rate decreases 
by as much as eight orders of magnitudes when the hydrogen participates in an 
intramolecular hydrogen bond. The rates of H/D exchange in a folded protein depend on 
structural fluctuations that result in open and closed conformations (126). According to 
such a model, exchange–labile hydrogen that is slow to exchange most often resides in 
the closed state, from which exchange cannot occur. Occasionally the protein 
experiences a motion that brings the amide hydrogen to an open state from which 
exchange can occur. The opening motion proceeds with the rate constant ko and the 
closing motion with the rate constant kc. Exchange can occur with the rate constant ki 
from the open form. The observed rate constant kex from such a model is given by 
equation 11.  
NHcl NHop ND
ko
kc
ki
 
)( cioiex kkkkk +=    (11) 
Once an amide hydrogen reaches the open state, the balance between closing 
without exchange and moving forward with exchange dictates the two limits EX1 and 
EX2. In the EX2 limit of hydrogen exchange, kc >> ki, and the equation simplifies to 
ieqicoex kKkkkk == )( . Here, ko/kc is equivalent to the equilibrium constant for opening, 
Keq. In most studies, ki depends on the hydroxide ion concentration, so kex represents an 
apparent bimolecular. Since ki can be calculated from model compound data, exchange 
rates from the EX2 limit can be used to determine Keq if the model is correct. In the EX1 
limit of hydrogen exchange, ki >> kc and equation 11 simplifies to kex = ko; exchange 
always occurs from the open state before the amide proton closes to exchange. The two 
mechanisms can be distinguished by the the isotopic pattern of the deuterium exchanged 
fragment seen in the mass spectrometer (Figure 20) (122). H/D exchange via an EX2 
mechanism increases the mass of peptide and shows a binomial distribution of peaks 
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(Figure 21). An increase in mass due to deuteriums can be calculated from the centroid 
of mass. From the time course of exchange of deuteriums, one can determine the rate 
constants for exchange using equation 12. 
 
A)      B)  
FIGURE 21. Isotopic patterns of deuterium atom exchanged fragments: A) EX2 
mechanism and B) EX1 mechanism (122). 
 
RESULTS 
Identification of peptic fragments. Prior to H/D exchange experiments, TyrH 
peptic peptides were sequenced by HPLC/ESI-MS/MS. Pepsin-digested TyrH was 
separated on HPLC and the eluted fragments were sequenced on a mass spectrometer as 
described in Experimental Procedures. The sequence of peptide fragments in each scan 
(Table 9) was identified by TurboSEQUEST software, a search tool from BioWorks 
(Thermo Finningan, Version 3.1). The identities of the peptic peptides from the 
experiment were further confirmed from a peptic peptide map of TyrH generated with 
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MS-digest program by Peter Baker Instructions (http://prospector.ucsf.edu 
/ucsfhtml4.0/msdigest.htm). From this 71% of the TyrH sequence (Table 9) was 
obtained from single run and 72% of the sequence was identified from different runs 
(Figure 22). The pepsin digested TyrH fragments were found to be highly reproducible 
under the final optimized conditions. 
 
Table 9. Sequence of Peptic Peptides of TyrH. 
Scan(s) Sequence MH+ Charge 
568 - 574 L.ASLGASDEE.I 878.37 1 
572 - 577 L.KGLYATHACREHLEG.F 1684.82 3 
584 - 588 Q.YIRHASSPMHSPEPDCC.H 1929.80 3 
589 Q.YIRHASSPMHSPEPDCC.H 1929.80 2 
610 - 614 F.EAKIHHLETRPAQRPLAGSPHLEY.F 2750.45 3 
640 - 644 L.HTLAHALSAIS.- 1120.61 2 
661 L.LERYCGY.R 903.40 2 
664 - 669 F.SQDIGL.A 632.33 1 
668 - 672 L.FSLRGTKPSSL.S 1192.67 2 
673 - 677 A.FQYKHGEPIPHVEY.T 1743.85 3 
676 - 684 Y.VTLKGLYATHACREHLEG.F 1998.02 3 
714 - 716 L.LSSYGEL.L 768.38 1 
725 Y.GELLHSLSEE.P 1113.54 2 
736 - 741 E.IAFQYKHGEPIPHVEYTAEE.I 2358.14 3 
742 E.IAFQYKHGEPIPHVEYTAE.E 2229.10 3 
748 - 752 A.FRVFQCTQ.Y 1028.50 2 
760 - 764 A.DRTFAQF.S 884.43 2 
762 L.LHSLSEEPEVRAFDPDTA.A 2012.96 3 
765 - 768 A.VVFEERDGNAVL.N 1347.69 2 
769 - 772 E.IAFQYKHGEPIPHVEY.T 1927.97 3 
773 - 778 E.FGLCKQNGEL.K 1108.55 2 
776 A.IDVLDSPHTIQRSLE.G 1722.90 2 
781 E.IATWKEVY.V 1009.54 2 
785 A.IDVLDSPHTIQRSLE.G 1722.90 3 
793 L.ADRTFAQF.S 955.46 2 
798 - 801 L.SRAVKVFETF.E 1183.65 2 
800 - 804 F.LKERTGFQLRPVAGL.L 1684.99 3 
817 - 820 L.IEDARKEREAAAAAAAAAVASSEPGNPLEA.V 2936.47 3 
821 - 824 F.VRFEVPSGDL.A 1118.58 2 
825 - 830 L.DKCHHLVTKFDPDLDL.D 1895.93 3 
825 - 830 E.LDKCHHLVTKFDPDLD.L 1895.93 3 
826 - 828 C.HELLGHVPMLA.D 1216.65 2 
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Table 9. Continued. 
Scan(s) Sequence MH+ Charge 
829 - 832 E.LDKCHHLVTKFDPDLDL.D 2009.02 3 
836 L.DKCHHLVTKFDPDLDL.D 1895.93 2 
840 - 844 E.FGLCKQNGELKAYGAGL.L 1768.91 3 
852 F.QLRPVAGLL.S 966.61 2 
868 - 872 C.HELLGHVPML.A 1145.61 2 
870 - 873 L.LSARDFL.A 821.45 2 
888 - 892 Y.FVRFEVPSGDL.A 1265.65 2 
890 S.LAFRVFQCTQ.Y 1212.62 2 
893 - 896 F.LKERTGFQLRPVAGLL.S 1798.07 3 
894 E.FGLCKQNGELKAYGAGLLSS.Y 2056.05 3 
905 - 908 T.WKEVYVTL.K 1037.57 2 
906 L.EDVSRFLKERTGFQLRPVAGL.L 2418.33 3 
925 L.KAYGAGLLSSYGEL.L 1428.74 2 
928 - 932 A.IDVLDSPHTIQRSLEGVQDEL.H 2364.20 3 
929 - 933 A.IDVLDSPHTIQRSLEGVQDEL.H 2364.20 2 
942 L.AIDVLDSPHTIQRSLEGVQDEL.H 2435.24 2 
944 L.AIDVLDSPHTIQRSLEGVQDEL.H 2435.24 3 
948 - 952 E.PEVRAFDPDTAAVQPYQDQTYQPVYF.V 3045.43 2 
960 E.IATWKEVYVTL.K 1322.74 2 
965 - 985 E.FGLCKQNGELKAYGAGLLSSYGEL.L 2518.27 3 
969 L.LSSYGELLHSLSEE.P 1563.75 2 
984 Q.DELHTLAHALSAIS. 1477.77 2 
Periods indicates the pepsin sites. 
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ATPSAPSPQPKGFRRAVSEQDAKQAEAVTSPRFIGRRQSLIEDARKEREAAAAAA
AAAVASSEPGNPLEAVVFEERDGNAVLNLLFSLRGTKPSSLSRAVKVFETFEAKI
HHLETRPAQRPLAGSPHLEYFVRFEVPSGDLAALLSSVRRVSDDVRSAREDKVP
WFPRKVSELDKCHHLVTKFDPDLDLDHPGFSDQVYRQRRKLIAEIAFQYKHGEP
IPHVEYTAEEIATWKEVYVTLKGLYATHACREHLEGFQLLERYCGYREDSIPQL
EDVSRFLKERTGFQLRPVAGLLSARDFLASLAFRVFQCTQYIRHASSPMHSPEPD
CCHELLGHVPMLADRTFAQFSQDIGLASLGASDEEIEKLSTVYWFTVEFGLCKQ
NGELKAYGAGLLSSYGELLHSLSEEPEVRAFDPDTAAVQPYQDQTYQPVYFVSE
SFNDAKDKLRNYASRIQRPFSVKFDPYTLAIDVLDSPHTIQRSLEGVQDELHTLA
HALSAIS
 
FIGURE 22. TyrH peptic peptide map. The arrows indicate the individual peptides 
observed from MS/MS. Loop residues are shown in bold. 
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H/D exchange studies and time dependent deuterium incorporation. The 
previous analysis of W166F/F184W/W233F/W372F TyrH by fluorescence anisotropy 
spectroscopy indicated that the loop (residues 177-200) is less mobile in the presence of 
substrates. The structural changes of TyrH on substrate binding were further probed with 
H/D exchange. It was initiated by dilution of rTyrH into 20 volumes of D2O. The extent 
of deuteration of the loop peptide was followed as a function of time at pH 7.0. At 
regular intervals samples were collected, quenched and digested with pepsin. The peptic 
peptide fragments were separated by HPLC and the fragments were directly sent to a 
mass spectrometer as described in Experimental Procedures. The loop fragment having 
residues 174-189 (DKCHHLVTKFDPDLDL) with mass 1895.93 and charge +3 (Table 9) 
were analyzed for deuterium incorporation. This loop fragment with M/Z value of 632.6 
was identified from the total ion chromatograph (Figure 23A). The isotopically labeled 
peptide with M/Z value 632.6 was eluted around the same time in all the experiments. 
For each run, the binomial envelope formed due to deuterium incorporation onto the 
loop fragment (Figure 23B) was exported to MagTran, a software to identify the increase 
in mass.  
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(A)
(B) 
 
FIGURE 23. Characteristics of the loop fragment in A) H2O and B) D2O. The top panel 
is the total ion chromatograph of TyrH peptic peptides from MS-ESI, the loop fragment 
elution time in the middle panel and the lower panel is the enlarged region of the middle 
panel between 630.0 and 640.0 M/Z values. 
 
With time, an increase in the mass of the loop fragment was observed. The 
number of deuteriums on the loop was calculated. The kinetics of deuterium exchange in 
the presence and absence of ligands were analyzed. Figures 24, 25 and 26 are 
representative of the results obtained showing the number of deuteriums trapped onto the 
loop in the presence of ligands.  The data were fit to equation 12 where D is the number 
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of deuterium atoms present in a peptide, N is the number of peptide amide linkages in a 
segment, and ki is the hydrogen-deuterium exchange rate constant for each peptide 
linkage. Over the time course of exchange experiments, the increase in the mass of the 
loop was biphasic (Figure 24, 25 and 25; and Table 10) in all cases. The number of 
deuteriums at equilibrium was found to be between 5.7 ± 0.7 and 9.3 ± 0.6. Fast 
exchange rates of deuteriums were observed between 0.9 ± 0.01 to 2.25 ± 0.54 per min. 
Significant changes in slow deuterium exchange rates were observed for FeIII vs FeII. 
Where the rates were less than 0.005 ± 0.002 per min for TyrH (FeIII) and for TyrH 
(FeII) rates were 0.010 ± 0,003 to 0.022 ± 0.004 per min in the presence of ligands.  The 
exchange kinetics of loop did not change in the presence of tyrosine. Whatever the 
changes observed were due to pterin binding. 
The time course of dependent H/D of exchange of loop in TyrH (FeIII) was done 
in the presence of tyrosine and 6M5DPH4. 6M5DPH4 is a pterin analogue. The kinetics 
of deuterium exchange did not change in the presence of tyrosine whereas 6M5DPH4 
caused an increase in mass (Figure 24 and Table 10). The exchange rates associated with 
these deuteriums did not change. The total number of fast exchanging deuterium 
increased from 4 to 6 in the presence of 6M5DPH4. 
The time course of dependent H/D of exchange of loop in TyrH (FeII) was done 
under anaerobic conditions in the presence of tyrosine, 6MePH4 and BH4 (Figure 25 and 
26). 6MePH4 and BH4 reduce the TyrH (FeIII) to TyrH (FeII). The reconstitution of 
TyrH (FeII) was explained in Experimental Procedures. The kinetics of H/D exchange in 
the presence of pterin resulted in increase of number of deuteriums on the loop and no 
further change observed in the presence of tyrosine. In case of tyrosine, 6MePH4 and 
BH4, the slow exchange rates are found to be around 0.011 ± 0.004 per min (Table 10). 
The rates did not change in the presence of tyrosine for 6MePH4 whereas rates were 
increased two fold for BH4 (Table 10). NO mimics like oxygen. The kinetics of H/D 
exchange does not change from the BH4 and tyrosine (Figure 26 and Table 10).  
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FIGURE 24. Effects of ligands on the kinetics of deuterium incorporation into residues 
174-189 in TyrH (FeIII). TyrH alone (), 1 mM tyrosine (+), 5 mM 6M5DPH4 (), and 
both 5 mM 6M5DPH4 and 1 mM tyrosine (X). The lines are fits of the data to equation 
12. 
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FIGURE 25. Effects of ligands on the kinetics of deuterium incorporation into residues 
174-189 in TyrH (FeII) upon ligand binding. TyrH alone (), 1 mM tyrosine (+), 5 mM 
6MePH4 (), and both 5 mM 6MePH4 and 1 mM tyrosine (X). The lines are fits of the 
data to equation 12. 
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FIGURE 26. Effects of ligands on the kinetics of deuterium incorporation into residues 
174-189 in TyrH (FeII) upon ligand binding. TyrH alone (), 1 mM tyrosine (+), 1 mM 
BH4 (),  both 1 mM BH4 and 1 mM tyrosine (X), and 1mM BH4, 1 mM tyrosine and 
equimolar NO (). The lines are fits of the data to equation 12. 
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Table 10. Extent of Deuterium Incorporation and Their Rates.  
Conditions Mass at 
equilibrium  
Number 
of D 
k1 (min-1) Number 
of D 
k2 (min-1) 
TyrH (FeIII) 
No ligands 7.5 ± 0.7 4.1 ± 0.3 1.44 ± 0.29 3.4 ± 0.6 0.005 ± 0.002 
Tyr 7.8 ± 0.3 4.3 ± 0.2 1.80 ± 0.23 3.6 ± 0.3 0.005 ± 0.001 
6M5DPH4 9.1 ± 0.7 5.9 ± 0.3 2.25 ± 0.54 3.1 ± 2.6 0.002 ± 0.003 
Tyr+6M5DPH4 8.3 ± 0.9 6.3 ± 0.2 1.63 ± 0.19 2.1 ± 0.8 0.004 ± 0.002 
TyrH (FeII) 
No ligands 5.7 ± 0.2 3.2 ± 0.4 2.29 ± 1.27 2.5 ±0.3 0.015 ± 0.005 
Tyr 6.3 ± 0.3 3.4 ± 0.5 2.10 ± 1.12 2.9 ± 0.4 0.011 ± 0.004 
6MePH4 9.2 ± 0.4 4.4 ± 0.6 1.15 ± 0.38 4.9 ± 0.5 0.010 ± 0.003 
Tyr+6MePH4 9.3 ± 0.3 4.3 ± 0.6 1.39 ± 0.46 4.9 ± 0.4 0.013 ± 0.003 
BH4 9.3 ± 0.6 5.4 ± 1.1 1.12 ± 0.50 3.9 ± 0.8 0.010 ± 0.006 
Tyr+BH4 9.2 ± 0.2 4.9 ± 0.5 1.26 ± 0.29 4.3 ± 0.4 0.022 ± 0.004 
Tyr+BH4+NO 9.1 ± 0.1 5.2 ± 0.2 0.95 ± 0.01 3.8 ± 0.1 0.021 ± 0.002 
Conditions: Kinetics traces are illustrated in Figures 24, 25 and 26. The concentrations 
of ligands are 1 mM tyrosine, 5 mM 6M5DPH4, 5mM 6MePH4, 1mM BH4, and 143 µM 
NO. 
 
DISCUSSION 
The crystal structure of the PheH ternary complex shows a large conformational 
change in residues 131-155 upon binding of an amino acid. In contrast, the fluorescence 
anisotropy experiments in Chapter III suggested that binding of 6M5DPH4, a pterin 
analogue, to TyrH reduces the movement of the loop in that enzyme, but that binding of 
the amino acid has little effect on the loop. However, the results from the fluorescence 
experiments may not be directly relevant to catalysis. 6M5DPH4 is an inhibitor rather 
than a substrate, and the iron was in the inactive ferric form for those experiments. A 
lesser concern is that phenylalanine was used instead of the physiological substrate 
tyrosine. To investigate the conformational change in the loop under catalytic conditions, 
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that is, in the presence of natural substrates and with ferrous enzyme, H/D exchange 
analyses were employed. A variation of the techniques of Englander et al. (125) was 
used to detect structural changes upon ligand binding.  
Qualitatively, the results of the H/D analyses confirm the conclusions drawn 
from the fluorescence experiments. In the case of ferric TyrH, the H/D exchange kinetics 
of the loop did not change in the presence of tyrosine. In contrast addition of 6M5DPH4, 
a pterin analogue, increased the number of fast exchangeable deuteriums, indicating that 
the chemical environment of the loop had changed. The lack of further change observed 
in the presence of tyrosine indicates that the binding of tyrosine did not change the 
chemical environment of the loop beyond that produced by 6M5DPH4. These results are 
identical those of the fluorescence analyses. 
The H/D experiments could also be done with ferrous enzyme, unlike the 
fluorescence analyses. Both 6MePH4 and BH4 readily reduce TyrH (79, 80). As long as 
the experiments are done under anaerobic condition oxidation of the iron does not occur. 
The increased deuterium content of the loop in the presence of tetrahydropterin was due 
to an increase in the number of both the slow and the fast exchanging deuteriums. This is 
qualitatively comparable to the change produced by 6M5DPH4 and the ferric enzyme. 
However, there was a 2 to 4-fold increase in the rate constant for the slowly exchanging 
deuteriums, suggesting that there are differences in the conformational changes in the 
two different experiments and that the changes detected by fluorescence measurements 
are a subset of the conformational changes which occur during catalysis. There was also 
a difference in the kinetics of exchange with 6MePH4 versus BH4, the physiological 
substrate. In addition to the differences seen in the presence and absence of the 
tetrahydropterin, the presence of tyrosine resulted in a two-fold increase in the slow 
deuterium exchange rates with BH4, in contrast to the lack of an effect with 6MePH4. 
BH4 has a 1,2-dihydroxypropyl group at C6 instead of the methyl group found in 
6MePH4. The differences in the exchange kinetics between the two tetrahydropterin 
suggest that interactions with the dihydroxypropyl side chain are linked to the 
conformational change. While 6MePH4 is routinely used as a substrate for TyrH in place 
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of BH4, there are differences in the kinetics with the two different pterins. For example, 
there is much greater substrate inhibition with tyrosine when BH4 is used (52); indeed, 
that is one reason that BH4 is avoided.  
One difference between the experiments with the tetrahydropterins and with the 
catalytic reaction is that the latter involves oxygen. Oxygen could not be included with 
the other substrates, since that would have resulted in turnover. Nitric oxide has been 
used as an oxygen mimic for a number of iron proteins (127). The lack of any change in 
the exchange kinetics when NO was included suggests that oxygen binding is not linked 
to a conformational change prior to catalysis.  
In conclusion, these results support the conclusions drawn from the fluorescence 
anisotropy experiments: amino acid binding does not change the mobility of the loop or 
changes it very little, whereas pterin binding substantially decreases its mobility. These 
results are also consistent with a kinetic mechanism (52) in which tetrahydropterin binds 
first to establish a binding pocket for the amino acid. However, the results do not 
identify the critical conformational changes or changes required for initiation of 
catalysis. Identification of those will require further experiments. These will include 
analysis of the exchange dynamics of the remainder of the peptic peptides in TyrH and 
studies with mutant TyrH enzymes, especially F184A.  
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CHAPTER V 
SUMMARY 
The studies presented here have focused on the role of protein structure on 
regulation and catalysis in TyrH. In Chapter II, the effect of phosphorylation on the 
human TyrH isoforms were determined. The four isoforms were cloned and 
characterized. Phosphorylated and unphosphorylated isoforms were used to study the 
binding of DOPA and dopamine to understand the regulatory mechanism.  The Kd value 
for DOPA increases two fold for isoform 1 upon phosphorylation and this value 
decreases as the length of the regulatory domain is increased. Dopamine binds very 
tightly to all four isoforms, upon phosphorylation Kd value increased about 30 fold. 
Dopamine was found to be the key regulating catecholamine for hTyrH isoforms rather 
than DOPA. 
 Chapters III and IV focused on loop movement using fluorescent anisotropy and 
H/D exchange LC/MS mass spectroscopy. In TyrH, loop residues 177-200 play an 
important role in binding of tyrosine and DOPA formation. 6M5DPH4 binds to apo and 
holoenzymes and decreases the loop mobility. Iron seems to play an important role in 
binding of the phenylalanine. Further characterization of the mobility of the tryptophan 
in the loop by frequency-domain anisotropy demonstrated a decreased amplitude of the 
local rotation in the presence of 6M5DPH4 alone.  The structural changes were further 
probed with H/D exchange mass spectroscopy. The results confirmed that the change in 
the chemical environment of the loop is dependent on the pterin which does not change 
with the presence or absence of tyrosine. The results show the conformational change in 
the loop is primarily due to pterin binding. The conformational change in the loop 
produced upon pterin binding allows the amino acid to bind to TyrH and the chemistry 
to take place. This supports the kinetics of alanine scanning mutations of loop residues in 
TyrH.  
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